[COMPANY_001] Research and Development
MAS825
CMAS825F12201 / [STUDY_ID_REMOVED]
A Phase 2, randomized, placebo -controlled, participant and 
investigator blinded, multi -center study to assess efficacy 
and safety of MA S825 for the treatment of SARS-CoV-2 
infected patients w ith COVID -19 pneumonia an d impaired 
respi[INVESTIGATOR_13521] y function
Document type: Amended Protocol Version
EUDRACT number: NA
Version number: v01(Clean )
Clinical Trial Phase: II
Release date: 03-Jul-2020
Property of [COMPANY_001]
Confidential
May not be used, divulged, published, or otherwise disclosed
without the consent of [COMPANY_001]
Clinical Trial Protocol Template Version 3.0 dated 31 -Jan-2020
[COMPANY_001] Confidential Page 2of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Table of contents
Table of contents ................................................................................................................. [ADDRESS_1178273] of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 11
Protocol summary .............................................................................................................. 18
1Introduction ....................................................................................................................... 23
1.1 Background ............................................................................................................ 23
1.1.1 Rationale for targeting the inflammasome effector cy tokines in 
patients with COVID -19 pneumonia and impaired respi[INVESTIGATOR_701831]. ................................................................................................ 23
1.1.2 Excessive inflammasome activation by  [CONTACT_847518] .................................................................................................... 24
1.1.3 Translational evidence that IL1β and IL- 18 are pi[INVESTIGATOR_847473] -19 patients .......................................................... 25
1.1.4 Summary ............................................................................................... 25
1.2 MAS825 ................................................................................................................. 26
1.2.1 Nonclinical data .................................................................................... 26
1.2.2 Clinical data ................................
.......................................................... 26
1.3 Purpose .................................................................................................................. 27
2Objectives and endpoints ................................................................................................... 27
2.1 Primary  estimands ................................................................................................. 29
2.2 Secondary  estimands ................................
............................................................. 29
3Study  design ...................................................................................................................... 29
4Rationale ............................................................................................................................ 31
4.1 Rationale for stud y design ................................
..................................................... 31
4.2 Rationale for participant numbers and endpoint .................................................... 32
4.3 Rationale for choice of background therap y.......................................................... 32
4.4 Rationale for dose/regimen, du ration of treatment and follow -up ........................ 33
4.5 Purpose and timing of interim anal yses/design adaptations .................................. 35
4.6 Risks and benefits ................................
.................................................................. 35
4.6.1 Potential benefits and risks to study  participants .................................. 35
4.6.2 Potential risks to study  participants ....................................................... 36
4.7 Overall risk benefit ................................................................................................ 38
4.8 Blood sample volume ................................
............................................................ 38
  Commercially Confidential Information (CCI)
[COMPANY_001] Confidential Page 3of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
5Study  Population ................................ ................................ ................................ ............... 38
5.1 Inclusion criteria .................................................................................................... 38
5.2 Exclusion criteria ................................................................................................... 39
6Treatment ........................................................................................................................... 40
6.1 Study  treatment ...................................................................................................... 40
6.1.1 Investigational and control drugs .......................................................... 40
6.1.2 Additional study  treatments .................................................................. 41
6.1.3 Treatment arms/group ........................................................................... 41
6.2 Other treatment(s) .................................................................................................. 41
6.2.1 Concomitant therap y ............................................................................. 41
6.3 Participant numbering, treatment assignment, randomization .............................. 42
6.3.1 Participant numbering ........................................................................... 42
6.3.2 Treatment assignment, randomization .................................................. 42
6.4 Treatment blinding ................................................................................................. 43
6.5 Dose escalation and dose modification
.................................................................. 45
6.6 Additional treatment guidance ............................................................................... 45
6.6.1 Treatment compliance ........................................................................... 45
6.6.2 Recommended treatment of adverse events .......................................... 46
6.6.3 Emergency  breaking of assigned treatment code .................................. 47
6.7 Preparation and dispensation ................................................................................. 47
6.7.1 Handling of study  treatment and additional treatment .......................... 47
6.7.2 Instruction for prescribing and taking stud y treatment ......................... 48
7Informed consent procedures ................................
............................................................ 48
8 Visit schedule and assessments ......................................................................................... 50
8.1 Screening ............................................................................................................... 53
8.1.1 Information to be collected on screening failures ................................. 53
8.2 Participant demographics/other baseline characteristics
....................................... 53
8.2.1 Demographic information ..................................................................... 53
8.2.2 Prior and concomitant medications....................................................... 54
8.3 Efficacy ................................................................
.................................................. 54
8.3.1 Vital signs and ox ygen saturation and use ............................................ 54
8.3.2 APACHE II severity  of disease score ................................................... 54
8.3.3 Clinical status (9 -point ordinal scale) ................................................... 55
8.3.4 CRP and Ferritin ................................................................................... 55
8.3.5 Appropriateness of efficacy  assessments .............................................. 55
8.4 Safety ................................................................
..................................................... 56
[COMPANY_001] Confidential Page 4of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
8.4.1 Laboratory  evaluations .......................................................................... 56
8.4.2 Physical examination ............................................................................ 57
8.4.3 Height and weight ................................................................................. 57
8.4.4 Electrocardiogram (ECG) ..................................................................... [ADDRESS_1178274] -study  treatment .......................................................... 64
10Safety  monitoring a nd reporting ........................................................................................ 64
10.1 Definition of adverse events and reporting requirements ...................................... 64
10.1.1 Adverse events ................................
...................................................... 64
10.1.2 Serious Adverse Events ......................................................................... 66
10.1.3 SAE reporting................................
........................................................ 67
10.1.4 Pregnancy  reporting .............................................................................. 67
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ 68
10.2 Additional safet y monitorin g................................................................................. 68
10.2.1 Liver safety  monitoring ......................................................................... 68
10.2.2 Data Monitoring Committee ................................
................................. 69
11Data Collection and Database management ...................................................................... 69
11.1 Data collection
....................................................................................................... 69
11.2 Database management and quality  control ............................................................ 69
11.3 Site monitoring ...................................................................................................... 70
   Commercially Confidential Information
[COMPANY_001] Confidential Page 5of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
12Data analy sis and statistical methods ................................ ................................ ................ 71
12.1 Analy sis sets .......................................................................................................... 71
12.2 Participant demographics and other baseline characteristics ................................. 71
12.3 Treatments ............................................................................................................. 71
12.4 Analy sis of the primary  endpoint(s)/estimand(s) .................................................. 72
12.4.1 Definition of primary  endpoint(s)/estimand(s) ..................................... 72
12.4.2 Statistical model, hy pothesis, and me thod of anal ysis.......................... 72
12.4.3 Handling of remaining intercurrent events of primary  estimand .......... 72
12.4.4 Handling of missing values not related to intercurrent event ............... 72
12.4.5 Sensitivity  analy ses for primary  endpoint/estimand ............................. 72
12.4.6 Supplementary  anal ysis......................................................................... 72
12.4.7 Supportive analy ses............................................................................... 72
12.5 Analy sis of secondary  endpoints/estimands .......................................................... 72
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s) .................................... 72
12.5.2 Safety  endpoints .................................................................................... 73
12.6 Analy sis of exploratory  endpoints ......................................................................... 74
12.9
Sample size calculation.......................................................................................... 75
12.9.1 Primary  endpoint(s) ................................
............................................... 75
12.9.2 Secondary  endpoint(s) ........................................................................... 75
13Ethical considerations and administrative procedures ...................................................... 75
13.1 Regulatory and ethical compliance ........................................................................ 75
13.2 Responsibilities of the investigator and IRB/ IEC.................................................. 76
13.3 Publication of study  protocol and res
ults............................................................... 76
13.4 Quality  Control and Quality  Assurance ................................................................. 76
14Protocol adhere nce............................................................................................................ 77
14.1 Protocol amendments ............................................................................................. 77
15References ................................
......................................................................................... 78
16Appendices ................................
........................................................................................ 82
16.1 Appendix 1: Anaphy laxis ...................................................................................... 82
16.2 Appendix 2: 9 -point ordinal scale determination .................................................. 83
16.3 Appendix 3: Liver event and laboratory  trigger definitions & follow -up 
requirements .......................................................................................................... 84
   Commercially Confidential Information Commercially  Confidential Information 
[COMPANY_001] Confidential Page 6of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
16.4 Appendix 4: I CU scores ................................ ................................ ......................... 86
16.5 Appendix 5: Severity  of hepatic impairment (Child- Pugh) ................................... [ADDRESS_1178275] of tables
Table 2-1 Objectives and related endpoints .......................................................... 27
Table 6-1 Investigational and control drug............................................................ 40
Table 6-
2 Blinding and unblinding plan................................
................................ 45
Table 6-3 Dose and treatment s
chedule ................................................................. 48
Table 8-1 Assessment schedule ................................
............................................. 50
Table 8-2 Clinical laboratory  tests (local) ............................................................. 57
Table 10
-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ......................................................................................... [ADDRESS_1178276] of figures
Figure 3 -
1 Study  design .......................................................................................... 30
        Commercially Confidential Information 
  Commercially Confidential Information 
    Commercially Confidential Information 
[COMPANY_001] Confidential Page 7of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
List of abbreviations
AE Adverse Event
AIDS Acquired immune deficiency s yndrome
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
AKI Acute Kidney Injury
ANCOVA Analysis of covariance
APACHE II Acute Physiology and Chronic Health Evaluation II
APTT Activated Partial Thromboplastin Time
ARDS Acute Respi[INVESTIGATOR_847474] -EPI [INVESTIGATOR_656954]&PS Chief Medical Office and Patient Safety
COVID -[ADDRESS_1178277] pressure
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CRP C-Reactive Protein
CSR Clinical study report
CT scan Computed Tomography Scan
CTC Common Terminology Criteria
CV coefficient of variation
CVD Cardiovascular Disease
DBP Diastolic Blood Pressure
dL deciliter
DMC Data Monitoring Committee
DNA Deoxyribonucleic Acid
DQF Data Query Form
DMC Data Monitoring Committee
eATP Extracellular adenosine triphosphate 
ECG Electrocardiogram
ECMO Extracorporeal membrane oxygenation 
[COMPANY_001] Confidential Page 8of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
eCRF Electronic Case Report Forms
EDC Electronic Data Capture
eGFR Estimated glomerular filtration rate
EOI End of Infusion
eSAE Electronic Serious Adverse Event
FAS Full Analysis Set 
FIH First-in-human 
FiO 2 Fraction of inspi[INVESTIGATOR_847475] -glutam yl transferase
GLP Good Laboratory Practice
h Hour
HA Health Authority
HDL High Density Lipoprotein
HBsAg Hepatitis B surface antigen
HV(s) Healthy Volunteers
i.v. intravenous
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonization of Technical Requirements for 
Pharmaceuticals for Human Use
ICU Intensive Care Unit
IEC Independent Ethics Committeee
IFN-g Interferon Gamma
IL 1β Interleukin 1 beta
IMM Inflammatory  monocyte macrophage
IN Investigator Notification
INR International Normalized Ratio
IP-10/CXCL10 Interferon gamma -induced protein 10 / C -X-C motif chemokine [ADDRESS_1178278] lower limit of normal
m Meter
M2Squared meter
Commercially Confidential Information  
[COMPANY_001] Confidential Page 9of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
MedDRA Medical dictionary for regulatory activities 
min minute
mg milligram (s)
mL milliliter(s)
mm3Cubic mi llimeter
mmHg Millim eters Mercury
MR scan Magnetic Resonance Scan
Nab Neutralizing antibody
NK cells Natural Killer cells
pM pi[INVESTIGATOR_847476] 2 Partial Pressures of Oxygen
PCR Polymerase Chain Reaction
PD Pharmacodynamic(s)
PEF Peak Expi[INVESTIGATOR_847477]’s formula
RBC red blood cell(s)
RRT Renal Replacement Therapy
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SARS -CoV-[ADDRESS_1178279] of Care
SpO2 Peripheral ox ygen saturation
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reaction
TBL Total Bilirubin
TD Study Treatment Discontinuation
TLR Toll Like Receptors
TNF alpha Tumor Necrosis Factor alpha
Commercially Confidential Information  
Commercially Confidential Information 
         Commercially Confidential Information 
[COMPANY_001] Confidential Page 10of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
ULN upper limit of normal
WBC white blood cell(s)
WHO World Health Organization 
WoC Withdrawal of Consent
WOCBP Women of Child Bearing Potential
        Commercially Confidential Information  
[COMPANY_001] Confidential Page 11of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Glossary  of terms 
Additional 
treatmentMedicinal products that may be used during the clinical trial as described in the 
protocol, but not as an investigational medicinal product (e.g. any background 
therapy)
Assessment A procedure used to generate data required by [CONTACT_49382] A biological specimen including, for example, blood (plasma, serum), saliva, 
tissue, urine, stool, etc. taken from a study participant 
Cohort A specific group of participants fulfilling certain criteria and generally treated at 
the same time
Control drug A study  drug (active or placebo) used as a comparator to reduce assessment 
bias, preserve blinding of investigational drug, assess internal study  validity, 
and/or evaluate comparative effects of the investigational drug
Cycles Number and timing or recommended repetitions of therapy are usually 
expressed as number of days (e.g., q28 days)
Dosage Dose of the study treatment given to the participant in a time unit (e.g. 100 mg  
once a day, 75 mg twice a day)
Electronic Data 
Capture (EDC)Electronic data capture (EDC) is the electronic acquisition of clinical study data 
using data collection systems, such as Web-based applications, interactive 
voice response systems and clinical laborator y interfaces. EDC includes the use 
of Electronic Case Report Forms (eCRFs) which are used to capture data 
transcribed from paper source forms used at the point of care
End of the clinical 
trialThe end of the clinical trial is define d as the last visit of the last participant or at 
a later point in time as defined by [CONTACT_760].
Enrollment Point/time of participant entry into the study at which informed consent must be 
obtained 
eSource (DDE) eSource Direct Data Entry (DDE) refers to the capture of clinical study  data 
electronically, at the point of care. eSource Platform/Applications combines 
source documents and case report forms (eCRFs) into one application, allowing 
for the real time collection of clinical trial information to sponsors and other 
oversight authorities, as appropriate
Estimand A precise description of the treatment effect reflecting the clinical question 
posed by [CONTACT_6553]. It summarizes at a population -level what the 
outcomes would be in the same patients under different treatment conditions 
being compared. Attributes of an estimand include the population, variable (or 
endpoint) and treatment of interest, as well as the specification of how the 
remaining intercurrent events are addressed and a populati on-level summary  
for the variable.
Healthy volunteer A person with no known significant health problems who volunteers to be a 
study participant 
Intercurrent events Events occurring after treatment initiation that affect either the interpretation or 
theexistence of the measurements associated with the clinical question of 
interest.
Investigational 
drug/ treatmentThe drug whose properties are being tested in the study
Medication 
numberA unique identifier on the label of medication kits
Mis-randomize d 
participantsMis-randomized participants are those who were not qualified for randomization 
and who did not take study treatment, but have been inadvertently randomized 
into the study 
[COMPANY_001] Confidential Page 12of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Other treatment Treatment that may be needed/allowed during the cond uct of the study  (i.e. 
concomitant or rescue therapy)
Part A sub-division of a study  used to evaluate specific objectives or contain different 
populations. For example, one study  could contain a single dose part and a 
multiple dose part, or a part in participants with established disease and in those 
with newly -diagnosed disease
Participant A trial participant (can be a healthy volunteer or a patient)
Participant number A unique number assigned to each participant upon signing the informed 
consent. This number is the definitive, unique identifier for the participant and 
should be used to identify the participant throughout the study  for all data 
collected, sample labels, etc.
Period The subdivisions of the trial design (e.g. Screening, Treatment, Follow -up) 
which are described in the Protocol. Periods define the study  phases and will 
be used in clinical trial database setup and eventually in analy sis
Personal data Participant information collected by [CONTACT_157058]. This data includes 
participant identifier information, study information and biological samples.
Premature 
participant 
withdrawalPoint/time when the participant exits from the study prior to the planned 
completion of all study drug administration and/or assessments; at this time all 
study drug administration is discontinued and no further assessments are 
planned
Randomization 
numberA unique identifier assigned to each randomized participant
Run-in Failure A participant who is screened but not randomized/treated after the run-in period 
(where run-in period requires adjustment to participant’s intervention or other 
treatment)
Screen Failure A participant who did not meet one or more criteria that were required for 
participation in the study
Source 
Data/DocumentSource data refers to the initial record, document, or primary  location from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSour ce
Start of the clinical 
trialThe start of the clinical trial is defined as the signature [CONTACT_201698] [CONTACT_847519]; includes investigational 
drug(s), control(s) or background therapy
Study treatment 
discontinuationWhen the participant permanently stops taking any of the study drug(s) prior to 
the defined study  treatment completion date (if any) for any reason; may or may 
not also be the point/time of study discontinuation 
Treatment 
arm/group A treatment arm/group defines the dose and regimen or the combination, and 
may consist of [ADDRESS_1178280], which might or might not be the same as the study 
treatment.
[COMPANY_001] Confidential Page 13of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Variable (or 
endpoint)The vari able (or endpoint) to be obtained for each participant that is required to 
address the clinical question. The specification of the variable might include 
whether the participant experiences an intercurrent event.
Withdrawal of 
study consent 
(WoC)Withdraw al of consent from the study  occurs only when a participant does not 
want to participate in the study any longer and does not allow any further 
collection of personal data 
[COMPANY_001] Confidential Page 14of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Commercially Confidential Information 
[COMPANY_001] Confidential Page 15of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Commercially Confidential Information
[COMPANY_001] Confidential Page 16of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Commercially Confidential Information
[COMPANY_001] Confidential Page 17of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Commercially Confidential Information
[COMPANY_001] Confidential Page 18of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Protocol summary
Protocol number CMAS825F12201
Full Title A Phase 2, randomized, placebo -controlled, participant and investigator 
blinded, multi-center study  to assess efficacy  and safety of MAS825 for the 
treatment of SARS -CoV-[ADDRESS_1178281] of care (SoC) compared with placebo and SoC 
in controlling the inflammatory syndrome and resultant acute respi[INVESTIGATOR_1421] (ARDS) in hospi[INVESTIGATOR_847478] -
[ADDRESS_1178282] grossly eleva ted levels of IL -1β and it s downstream 
cytokine IL-6, as well as IFN-g and IP-10 (CXCL10), both downstream 
markers of IL-[ADDRESS_1178283] the autoinflam matory response, limiting further alveolar damage and 
improving clinical outcomes. 
Primary Objective(s) To evaluate the effect of MAS825, compared with placebo , on the Acute 
Physiology and Chronic Health Evaluation II (APACHE II) score
Secondary 
ObjectivesThe secondary objectives of this study are:
To evaluate the effect of MAS825, compared with placebo, on
inflammatory  status
To evaluate the effect of MAS825, compared with placebo, on clinical
status
To evaluate the safety of MAS825, compared with placebo
Commercially Confidential Information
[COMPANY_001] Confidential Page 19of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Study design This is a Phase 2, randomized, placebo -controlled, participant and 
investigator blinded, multi-center study  to assess efficacy  and safety of 
MAS825 for the treatment of SARS -CoV-2 infected patients with COVID -19 
pneum onia and impaired respi[INVESTIGATOR_13521] y function.
The study consists of five p arts:
1.Screening / Baseline / Treatment (Day -1 to 1) : lasts up to a maximum
of 24 hours and com prises a screening / baseline assessment. This visit
will be used to confirm that the study inclusion and exclusion criteria are
met and serves as baseline asses sment prior to randomization. Baseline
blood tests will be performed in all patients; those who screen fail
because of study inclusion / exclusion criteria (e.g., serum CRP, liver
function tests), will not undergo randomization. Eligible patients will
receive a single i.v. infusion of  MAS825 or placebo on Day -1
to 1.
2.Treatment period (Day 2-15): Study assessments to be conducted
every 2 days for hospi[INVESTIGATOR_9643]. If patients are discharged from the
hospi[INVESTIGATOR_847479] y 15, assessm ents on the da y of discharge should be
performed according to the schedule listed under Day 15 and patient
shou ld return to the site for the Day 15 assessment (all other visits
between discharge and Day 15 can be om itted). If hospi[INVESTIGATOR_847480] 15, then home nursing services may  be used to support
this last visit where these are available in acco rdance with local
guidelines and should include all possible assessments (e.g. oxygen
saturation with portable monitors). In case hom e nursing is not possible,
patients will be contact[CONTACT_132299] 15.
3.Follow -up (Day 16-29): After completion of the treatment period,
patients will be observed until Day 29 or discharged from hospi[INVESTIGATOR_307],
whichever is sooner. Study assessments to be conducted every 2 days
for domiciled patients.
Where patients are discharged from hospi[INVESTIGATOR_41337] 29, a study  visit
cond ucted by [CONTACT_847520] 29 (all other visits between
discharge and Day 29 can be omitted).
4.Safety follow -up visit assessment (Day 45): A follow -up visit will be
conducted at Day 45 if the patient is hospi[INVESTIGATOR_057]. Ifpatients are
discharged fro m hospi[INVESTIGATOR_41337] 45, a study visit will be conducted
by [CONTACT_45347] 45.
5.End of Study/Safety follow -up visit assessment (Day 127) : A follow -
up visit for safety  will be conducted at Day 127 if the patient is
hospi[INVESTIGATOR_057]. If patients are discharged from hospi[INVESTIGATOR_41337] 127, a
study visit will be conducted by [CONTACT_45347] 127.
Study population Approximately 120 male and female patients  aged18 years and above .
The study population includes adult male and female SA RS-CoV-2 infected 
patients who are hospi[INVESTIGATOR_701778] -19 pneumonia and 
impaired respi[INVESTIGATOR_4806].
  CCI
[COMPANY_001] Confidential Page 20of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Key Inclusion 
criteriaParticipants eligible for inclusion in this study  must meet all of the following 
criteria:
1.Male and female patients aged ≥ 18years at screening
2.Signed Informed Consent Form (ICF) by [CONTACT_847521], or, when the patient is not capable of giving consent, by [CONTACT_847522]/authorized representative (if allowed according to local 
requirements) 
3.Clinically diagnosed with the SARS -CoV-2 virus by [CONTACT_12036] (PCR) or by [CONTACT_847523] 
7days prior to randomization
4.Hospi[INVESTIGATOR_21391] -19-induced pneumonia evidenced by [CONTACT_13190] x-
ray, com puted tom ography scan (CT scan) or magnetic resonance scan 
(MR scan) (taken within 5 days prior to randomization)
5.Impaired respi[INVESTIGATOR_13521] y function, defined as peripheral oxygen saturation 
(SpO 2) ≤93% on room air or partial pressure of oxygen (PaO 2) / fraction 
of inspi[INVESTIGATOR_1401] (FiO 2) <300 millimeter of mercury  (mmHg) at ti me of 
screening For cities located at altitudes greater than 2500 m above sea 
level, these will be substituted with SpO 2<90% and PaO 2/FiO 2<250 
mmHg
6.Acute Physiologic Assessment and Chronic Health Evaluation 
(APACHE) II score of ≥10 at time of screening 
7.CRP ≥20 mg/L or ferritin level ≥600 μg/L at screening
8.Body weight between 45 kg and 145 kg, inclusive, at screening
9.Ability to comply with the study protocol, in the investigator's judgment
Key Exclusion 
criteria1.History of hypersensitivity to the investigational treatment or their 
excipi[INVESTIGATOR_201021]
2.Suspected active or chronic bacterial (including Mycobacterium 
tuberculosis), fungal, viral, or other infection with the exception ofSARS -
CoV-[ADDRESS_1178284] 30 days or 5 half-lives 
(whichever is the longer) for immunomodulatory therapeutic antibodies 
or prohibited drugs (see Section [IP_ADDRESS] , with the exception of anti-viral
therapi[INVESTIGATOR_847481] 
For COVID -19 infection, ongoing corticosteroid treatment is 
permitted at doses as per local SoC
For non-COVID -19 disorders, ongoing corticosteroid treatment is 
permitted at doses up to and including prednisolone 10 mg daily or 
equivalent (see Section 6.2.1 Concomitant therapy )
7.Serum alanine transaminase (ALT) or aspartate transaminase 
(AST) >5times upper limit of normal detected within 24 hours at 
screening/baseline (according to local laboratory reference ranges) or 
other evidence of severe hepatic impairment (Child -Pugh Class C, see 
Appendi x 5)
[COMPANY_001] Confidential Page 21of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
8.Absolute peripheral blood neutrophil count of ≤1000/mm3
9.Estimated GFR (eGFR) ≤30 mL/min/1.73m2(based on CKD -EPI
[INVESTIGATOR_14420])
10.Pregnant or breastfeeding, or positive urine or serum pregnancy test in
a pre- dose examination
11.Any serious medical condition or abnormality of clinical laboratory tests
that, in the investigator’s judgment, precludes the patient’s safe
participation in and completion of the study
12.Women of child-bearing potential, defined as all women physiologically
capable of becoming pregnant, unless they agree to abstain from any
sexual intercourse for a total of 29days after randomization (the 14- day
treatment period plus a 14-day follow -up period ).
13.Current participation in any other investigational trial s, with the
exception of (not yet) appro ved COVID -19 therapi[INVESTIGATOR_847482] (local) standard of care (also see Section [IP_ADDRESS] . for
Prohibited drugs).
Study treatment Patients will receive a single dose of MAS825  i.v.in addition to
Standard of Care, or placebo in addition to Standard of Care
Treatment of 
interestThe randomized treatment (the investigational treatment MAS825 in addition 
to SoC or control treatment of SoC alone)
Efficacy 
assessmentsAPACHE II severity of disease score on Day 15 or on day of discharge
(whichever is earlier) with worst case imputation for death
9-point ordinal scale ( Appendix 2 ):
Survival without the need for invasive mechanical ventilation at
Days 15 an d 29
At least one level improvement in clinical status at Days 15 and
29
Clinical status over time
Serum CRP levels and ferritin
Pharmacodynamic 
assessments The pharmacodynamic objective for this study  is to characterize the 
pharmacodynamic effects of MAS825 in patients with COVID -19 pneum onia 
via longitudinal measures of a num ber ofanalytes relative to 
baseline including the following:
CRP, ferritin, LDH, absolute whole blood neutrophil count, D- dimer,
troponin
              Commercially Confidential InformationCCI
[COMPANY_001] Confidential Page 22of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Key safety 
assessmentsIncidence and severity of adverse events / serious adverse events
Clinically significant changes in laboratory measures
Vital signs, electrocardiogram (ECG), height and weight
Physical examination
Chest X -ray(CXR), CT or MR scan
Other assessments 
Data analysis The primary  endpoint will beevaluated by [CONTACT_847524] (age, anti-viral 
therapy, andpresence of ≥1comorbidities) as factors and baseline 
APACHE -II score as a covariate.
For efficacy  and pharmacodynamics endpoints, descriptive statistics (mean, 
standard deviation, median, minimum and maximum) will beprovided for 
variables that are of the numeric or continuous type, while frequenc y 
distributions (with number and percent) will be provided 
forcategorical variables.
All listings and tables will be presented by [CONTACT_1570].
Key words COVID -19, pneumonia, SARS -Cov2, APACHE II, MAS825, inflammasome
 Commercially Confidential Information
[COMPANY_001] Confidential Page 23of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
1 Introduction
1.1 Background
As of April 16, 2020, severe acute respi[INVESTIGATOR_19960] 2 (SARS -CoV -2) infection 
has been confirmed in over 2 Million people worldwide, with over 137,000 deaths to date due 
to coronavirus disease 2019 (COVID -19). The mortality  rate of approximately  4-5% is 
significantl y higher than that seen with seasonal influenza (less than 1%) and between 5-10% 
of COVID- 19 patients develop lung injury, respi[INVESTIGATOR_847483] (ARDS) requiring prolonged ventilator support over weeks that results in 
intensive care units, hospi[INVESTIGATOR_307] s and health care s ystems becoming overwhelmed.
ARDS is characterized by [CONTACT_23131]-inflammatory  cytokine release, inflammatory  cellular infiltrate 
and cell death resulting in severe pulmonary  damage and the development of respi[INVESTIGATOR_847484]-expi[INVESTIGATOR_847485] (PEEP) to 
maintain life. In patients with a prior history  of hypertension, diabetes and cardiovascular 
disease, poor outcomes have been reported that may be as result of poor underl ying cardiac 
reserve meaning that patients develop cardiac failure in response to ventilation, with pulmonary  
edema further exacerbating respi[INVESTIGATOR_33078] ( Zhou et al 2020).
Targeted treatment of the underly ing hyper-inflammato ry syndrome that occurs after initial 
SARS -CoV -[ADDRESS_1178285] pathogens, including viruses. 
Pattern recognition receptors (PRR) are part of this system and are sensors for microbial 
structures. To safeguard the immune response, viruses can be sensed by [CONTACT_847525], but also distinct classes of innate immune receptors, such as the nucleic -acid sensors, 
MDA -5 and RIG-I or members of inflammasome and Toll-like receptor (TLR) families. 
These sensors initiate a protective response that begins with the production of pro -inflammatory  
cytokines, such as type I interferons that restrict viral replication. In a subsequent wave of the 
host reaction to viruses, danger signals are released as tissues are damaged and cells are killed 
by [CONTACT_84096]. The recognition of these danger signals by [CONTACT_847526] ( Horvath et al 2011, Franchi et al 2014 ). 
A key sensor for danger signals released from dying cells is the NLRP3 inflammaso me, which, 
upon activation, leads to the production and release of active IL-1β and IL-18. At low levels 
during initial stages of the disease, these cytokines amplify the innate immune response against 
viruses and promote the development of adaptive immune responses against the viruses 
(Tate et al 2016), providing long-term protection and reducing the risk of re-infection 
(Ichinohe et al 2009). However, when tissue damage from the virus or immune response is 
extensive, NL RP3 activation and the subsequent IL-1β and IL-18 production can be excessive 
[COMPANY_001] Confidential Page 24of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
and beyond what is required to support an adaptive response, contributing to morbidity  and 
mortali ty.
The concerted actions of the inflammasome will lead to exacerbated edema by [CONTACT_847527], increased tissue damage through neutrophil reactive species, and excessive 
type II interferon through IL-18 on T cells and natural killer cells (NK cells), and elicit or 
exacerbate other broad pro-inflammatory  pathway s, including IL-6, IL-17 and tumor necrosis 
factor alpha (TNF (McAuley et al 2013 , Ren et al 2017 ). Consistent with NL RP3 play ing an 
underly ing role in pulmonary  pathology  during viral infection, it has been shown in mice 
infected with influenza that inhibition of the NLRP3 inflammasome in the sy mptomatic phase 
of the infection reduces systemic inflammation as well as lung pathology without impairing  
viral clearance (Tate et al 2016, Coates et al 2017 ,Jia et al 2018 ).
Tissue damage may also result in NLRP3 -independent release of IL-1β and IL-[ADDRESS_1178286] cell derived ch ymases, and T cell -and NK cell -derived granz yme B ( Afonina et al 2015). 
Particularl y, IL -[ADDRESS_1178287]  epi[INVESTIGATOR_847486] y further increased under inflammatory 
conditions such as in pulmonary sarcoidosis (Cameron et al 1999 ). IL-18 may not onl y activate 
Type 1 and Type 2 helper T 
cells and cytotoxic T cells but has been reported to promote NK 
cell -mediated tissue damage. This was shown in the context of fulminant hepatitis A viral 
infection, in which inherited IL-18BP deficiency (the natural scavenger of bioactive IL-18) 
resulted in ex cessive NK cell activation b y IL-18 and lead to the uncontrolled killing of human 
hepatocy tes (Belkay aet al 2019). Together, IL-1β and IL-18 can trigger innate and adaptive 
immune responses at the same time leading to exacerbated inflammation (Vanden Berghe et al 2014 ).
1.1.2 Excessive inflammasome activation by [CONTACT_847528] -19, non-invasive and invasive mechanical ventilation is applied as a life
supporting therap y. Mechanical stretch especially in the inflamed and stressed tissue is leading 
to extracellular ATP (eATP) release. eATP is sensed by [CONTACT_847529] P2X7 leading 
to potent NLPR3 inflammasome activation (Eckle et al 2007, Matsuy ama et al 2008
, 
Kuipers et al 2012, Liu et 
al 2019, Lv et al 2018, Wu et al 2013, Hasan et 
al 2017 , Liuet al 2019, 
Lv et al 2018 , Wu et al 2013
, Hasan et al 2017 ). This cascade of events further amplifies tissue 
inflammation and ARDS. In mice, IL-18 expression is increased in the lungs after 
intraperitoneal administration of lipopoly saccharide (LPS) or the occurrence of hemorrhage 
(reviewed inKaway ama et al 2012). Furthermore, a neutralizing anti -IL-18 antibody  has been 
shown to reduce the lung inflammatory  damage in a murine acute lung injury  model (Abdel 
Fattah et al 2015 ).
[COMPANY_001] Confidential Page 25of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
1.1.[ADDRESS_1178288] viral 
cytopathic effects. 
One of the key cytokines driving inflammation in the bronchoalveolar space in patients with 
ARDS is IL -1(Pugin et al 1996 ). Itenhances the production of other cy tokines with a longer 
half-life, such as IL-6, which accumulates in a sustai ned manner during the disease and 
(Olman et al 2004, Zhang et al 2004) The pathogenic role of IL - 1in the lungs is supported by 
[CONTACT_847530]-1via adenoviral gene transfer causes a local 
increase of the pro-inflammatory  cytokines IL-6 and TNF -α and a vigorous acute inflammatory  
tissue response, which then leads to progressive interstitial fibrogenesis ( Kolb et al 2001). 
Another cytokine that may have a pathogenic effect is IL-18. Levels of IL-18 are elevated in 
the serum of patients with SARS -CoV -1 
(Huang et al 2005). IL-
18 promotes lung fibrosis 
(Zhang et al 2019) and the production of Th1 cytokines that mediate alveolar epi[INVESTIGATOR_701777]. Consistent with this hypothesis, the expression of IL -[ADDRESS_1178289]  fibrosis ( Kang et al 2012 ). Interestingl y, an interferon -gamma t ype cytokine storm was 
described post SARS coronavirus infection (Kaway ama et al 2012). Thus, the existing data 
provide evidence for an important role of IL
-18 in lung injuries of different origins.
1.1.4 Summary
The inflammasome and the pi[INVESTIGATOR_847487] -1β, IL -18 and NLPR3 are known contributors 
to the hy per-inflammatory  response that results in severe pulmonary  tissue damage after initial 
SARS -CoV -1 and SARS -CoV -
2 infections. Treatment with a bispecific anti-IL-1/18 mAb 
(MAS825) in patients with severe COVID -19 pulmonary  disease is expected to reduce 
inflammation, reverse lung pathology  and may improve ventilation and clinical outcomes. 
Importantly , available evidence strongl y supports the concept that this treatment would not
increase viral persistence or other morbidity  related to a SARS -CoV -2 infection especially 
when administered at the later stage of the disease when respi[INVESTIGATOR_847488].
MAS825
, a bispecific anti-IL-1β/IL-18 mAb rapi[INVESTIGATOR_847489]-1β and IL-18. 
       Commercially  Confidential Information CCI
[COMPANY_001] Confidential Page 26of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
1.2 MAS825
1.2.1 Nonclinical data
1.2.2 Clinical data
Commercially Confidential Information
 Commercially Confidential Information
      Commercially Confidential Information
[COMPANY_001] Confidential Page 27of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
The overall preclinical and preliminary  clinical, safet y and laboratory  assessments are is 
considered adequate to justify  the continued development of MAS825 in patients with 
COVID -[ADDRESS_1178290] of care (SoC) compared with placebo and SoC in controlling the inflammatory  
syndrome and resultant ARDS in hospi[INVESTIGATOR_847478] -19 pneumonia 
and impaired respi[INVESTIGATOR_60324].
2 Objectives and endpoints
Table 2-1 Objectives and related endpoints
Objective(s) Endpoint(s)
Primary Objective(s)
To evaluate the effect of MAS825,
compared with placebo, on the Acute
Physiology and Chronic Health Evaluation II
(APACHE II) scoreEndpo int(s) for primary objective(s)
APACHE II severity of disease score on
Day15 or on day of discharge (whichever is
earlier) with w orst case imputation for death
Secondary Objective(s)
To evaluate the effect of MAS825,
compared with placebo on inflammatory
statusEndpoint(s) for secondary objective(s)
Serum C -reactive protein (CRP) levels and
ferritin
      Commercially Confidential Information
[COMPANY_001] Confidential Page 28of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Objective(s) Endpoint(s)
To evaluate the effect of MAS825,
compared with placebo, on clinical statusEndpoints based on the 9 -point ordinal scale 
(Appendix 2 ):
Survival without the need for invasive
mechanical ventilation at Days 15 and 29
At least one level improvement in clinical
status at Days 15 and 29
Clinical status over time
To evaluate the safety of MAS825,
compared with placeboNumber of participants with Adverse Event s
(AE), Serious Adverse Events (SAE),
clinically significant changes in labor atory
measures, and vital signs
   Commercially Confidential Information
[COMPANY_001] Confidential Page 29of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
2.[ADDRESS_1178291] is: What is the effect of MAS825 compared with 
placebo in SARS -CoV -2 infected patients with COVID -19 pneumonia and impaired respi[INVESTIGATOR_847490]- II severit y of disease score taking into account early  discharge from 
hospi[INVESTIGATOR_847491]?
The justification for the primary  estimand is that it will capture the combined effect of the study 
drug in patients who remain in hospi[INVESTIGATOR_34092] [ADDRESS_1178292] on death rate within 14 day s, in a ma nner than reflects clinical practice.
The primary  estimand is described by  [CONTACT_6570]:
1.Population: SARS -CoV -2 infected patients with COVI D-19 pneumonia and impaired 
respi[INVESTIGATOR_60324]. Further details about the population are provided in Section 5 .
2.Endpoint: APACHE II severit y of disease score on Day 15 or on day of discharge 
(whichever is earlier) with worst case imputation for death. Patients who die on Day  [ADDRESS_1178293]: the randomized treatment (the investigational treatment of MAS825 
or place bo)
4.Handling of remaining intercurrent events: Treatment discontinuation for any reason will 
be ignored and thus follow a treatment policy  strategy  i.e. participants who discontinue 
treatment will be treated in the same manner as those that continue the treatment as planned.
5.Summary  measure: The difference in variable means between treatments.
2.2 Secondary  estimands
Not applicable
3 Study  design
This is a Phase 2, randomized, placebo -
controlled, participant and investigator blinded, multi -
center study  to assess the efficacy  and safet y of MAS825 for the treatment of SARS -CoV -2 
infected patients with COVI D-19 pneumonia and impaired respi[INVESTIGATOR_60324] 
(Figure 3 -1).
[COMPANY_001] Confidential Page 30of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Figure 3-1 Study  design
The study  consists of five parts:
1.Screening / Baseline /Treatment (Day  -1 to 1): lasts up to a maximum of 24 hours and
comprises a screening / baseline assessment. This visit will beused to confirm that the study
inclusion and exclusion criteria are met and serves as baseline assessment prior to
randomization .Baseline blood tests will be performed in all patients; those who screen fail
because of study  inclusion / exclusion criteria (e.g., serum CRP, liver function tests), will
not undergo randomization.
Eligible patients will receive a single i.v.infusion of  MAS825 or placebo on
Day-1 to1 and will be observed until Day 15. Patients will be randomized as soon as
possible, but within a maximum of 24 hours after screening in a 1:1 ratio to receive either
treatment with MAS825 or placebo in addition to SoC. Randomization will be stratified
according to the following, all of whic h may  influence outcome in COVID -19:
age ( ≤65y ears, >65 years)
administration of any  anti-viral therap y (e.g., h ydrox ychloroquine, chloroquine,
convale scent plasma, remdesivir, faripi[INVESTIGATOR_847492], ritonavir, lopi[INVESTIGATOR_054]) as SoC (y es / no)
presence of ≥1 of the following comorbidities: diabetes, hypertension, cardiovascular
disease, chronic lung disease (y es / no)
2.Treatment period (Day  
2-15): Study  assessments to be conducted every  2  d ays for
hospi[INVESTIGATOR_9643]. If patients are discharged from the hospi[INVESTIGATOR_41337] 15,
assessments on the day of discharge should be performed according to the schedule listed
under Day 15 and patient should return to the site for the Day 15 assessment (all other visits
between discharge and Day  15 can be omitted). If a hospi[INVESTIGATOR_17399] l visit is not possible at Day  15,
then home nursing services may  be used to support this last visit where these are available
in accordance with local guidelines and should include all possible assessments (e.g. oxygen
saturation with portable monitors). In case home nursing is not possible, patients will be
contact[INVESTIGATOR_530] b y phone on day 15.
3.Follow -up(Day  16-29): After completion of the treatment period , patients will be observed
until Day 29 or discharged from hospi[INVESTIGATOR_307], whichever is sooner. Study  assessments to be
conducted every  2 day s for domiciled patients.
Ifpatients are discharged from hospi[INVESTIGATOR_41337]  29, a study  visit conducted b y
telephone will occur on Day  29 (all other visits between discharge and Day  29 can be
omitted) .
   CCI
[COMPANY_001] Confidential Page 31of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
4.Safety follow -up visit assessment (Day  45): A follow -up visit will be conducted at Da y 45
if the patient is hospi[INVESTIGATOR_057]. Ifpatients are discharg ed from hospi[INVESTIGATOR_41337] 45, a study
visit will be conducted by [CONTACT_45347]  45.
5.End of Study/Safety follow -up visit assessment (Day  127): A follow -up visit for safet y
will be conducted at Day 127if the patient is hospi[INVESTIGATOR_057]. Ifpatients are discharged from
hospi[INVESTIGATOR_41337]  127, a study  visit will be conducted by  [CONTACT_45347]  127.
4 Rationale
4.1 Rationale for study design
This is a randomized, placebo -controlled, participant -and investigator -blinded, multicenter 
study  in hospi[INVESTIGATOR_595347] ( ≥18 years) with COVID -19-associated pneumonia and 
impaired respi[INVESTIGATOR_60324]. This design supports the assessment of preliminary  efficacy  and 
as well as proof of concept and safet y of MAS825 in addition to SoC in this critically ill patient 
population.
The Screening / Baseline/Treatment visit will be used to confirm that the study inclusion and 
exclusion criteria are met and for performing baseline clinical observations and biological 
sampling (blood, urine). Patients meeting the inclusion and exclusion criteria will be acutely  
unwell and it is anticipated that recruitment and randomization will take place relativel y rapi[INVESTIGATOR_2478] y, 
with entry  into the study  taking place within a maximum of 24 hours of screening. This is 
justified based upon the clinical severit y of illness in patients admitted with COVID -19 
associated pneumonia and impaired respi[INVESTIGATOR_847493].
During theTreatment period patients will be randomized in a 1:1 ratio to receive either 
treatment with MAS825 i.v infusion or matching placebo in addition to SoC.
Randomization is justified as there is at present no clinical evidence that MAS825 will be 
efficacious in reducing disease severity  in COVID -
19 patients. The 1:[ADDRESS_1178294] minimizing the overall 
sample size. Stratification of randomization for age (≤65 years, >65 years), 
administration of 
any anti-viral therap y (yes / no) and presence of comorbidities (yes / no) is justified as these 
factors may  influence outcome in COVID -19 patients and we wish to ensure equal distribution 
of these variables between the two study  arms.
The Study Endpoints measure clinical status, clinical and in-hospi[INVESTIGATOR_95209], and laboratory 
values, including serum CRP, a key biomarker of inflammasome inhibition and safet y during 
and after the 14-day treatment period. These measurements are consistent with endpoints and 
measurement times for other studies of therapi[INVESTIGATOR_135297] -19.
The Study Follow -upperiod rationale is described in rationale for dose/regimen, duration of 
treatment and follow -up ( Section 4.4 )
     CCI
[COMPANY_001] Confidential Page 32of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
4.2 Rationale for participant numbers and endpoint
The total sample size of 120 participants ran domized in a 1:[ADDRESS_1178295] y 
for MAS825 allow a maximum of 60 participants to be treated.
The primary  endpoint for this study  is the APACHE II score (range 0 to 71) on day 15 or on 
day of discharge (whichever is earlier) with worst case imputation for death as this disease 
severit y score provides a comprehensive structured assessment of the clinical, physiological 
and laboratory  paramete rs that have been routinely  employ ed by [CONTACT_847531] -19 patients with pneumonia and 
respi[INVESTIGATOR_33078] (Yang et al 2020, Wang et al 2020 ). In particular, the APACHE II disease 
severit y score captures the clinicall y relevant physiologic variables for an aggregate score, with 
higher scores indicating more severe disease, with a median score of [ADDRESS_1178296] 
medical management of patients in this study . 
To establish clinical efficacy  based on APACHE II score, a sample size of 60 patients per 
treatment group provides 80% power when testing on an 10% 1-sided alpha level under the 
assumption that MAS825 in addition to SoC reduces the APACHE II score by3.6points more 
than placebo in addition to SoC (assumed standard deviation of 9.2 based onYang et al 2020 ).
Other clinical endpoints such as those derived from the 9-point ordinal scale were considered 
as primary  endpoints. However, since these endpoints were binary in nature, the sample sizes 
required to have sufficient power to show statistically  significant differences were much higher 
than those feasible with the limited available drug supply .
4.3 Rationale for choice of background therapy
There is at present no health authority  (HA) approved treatments for COVID -[ADDRESS_1178297] severel y affected. Current SoC in 
the European Union (EU) and [LOCATION_002] of America (US) includes a variet y of supportive 
thera pi[INVESTIGATOR_014], ranging from the administration of supplementary  oxygen to full intensive care 
support, alongside the use of antiviral agents and corticosteroids, though there is considerable 
inter-center variability  regarding the use of these. Local SoC is permitte d in all patients 
participating in the study, though every  effort will be made by  [CONTACT_847532].
Randomization for this study  stratifies for the administration of antiviral therap y e.g., 
hydroxychloroquine, chloroquine, remdesivir, faripi[INVESTIGATOR_847492], ritonavir, lopi[INVESTIGATOR_054], to ensure that 
treated and untreated patients are evenl y distributed between the two treatment arms.
      Commercially Confidential Information
[COMPANY_001] Confidential Page 33of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
4.4 Rationale for dose/regimen , duration of treatment and follow -up
Commercially Confidential Information 
[COMPANY_001] Confidential Page 34of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Similarly , the efficacious dose of MAS825 to neutralize IL-1β has been estimated from IL-1β 
measurements in COVID -19 patients with 
pneumonia and respi[INVESTIGATOR_1399] ( Huang et al 2020 ). The MAS825 dose level for 
the study  isfurther justified by ;
The dose will lead to rapid and simultaneous neutralization of all sy stemic free IL -I8 and
IL-1β.
This dose enables the treatment of severe COVID -19 where h yper-elevated levels of IL -1β
and IL -18 is expected
Commercially Confidential Information 
Commercially Confidential Information
CCI
[COMPANY_001] Confidential Page 35of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
The dose of MAS825 has been administered to heathy  volunteers with no identified safet y
concerns
The median hospi[INVESTIGATOR_95237] -19 has been reported to be 12 days with an interquartile 
range of 1 to 14 days (Cao et al 2020 ), justify ing treatment period selected. 
4.5 Purpose and timing of interim analy ses/design adaptations
4.[ADDRESS_1178298]  cytokine 
IL-6 (tocilizumab) in patients with cytokine release syndrome in the context of CAR -T therapy
and some evidence from case reports in COVID -19 patients with aplacebo- controlled Phase III 
clinical trial recently  initiated (Zhang et al 2020 , Mehta et al 2020, Ascierto et al 2020, 
[STUDY_ID_REMOVED]).
However, neither MAS825 nor other selective inhibitors of IL-1 and/or 
IL-18have previousl y been studied in patients with COVID -19 pneumonia. Therefore, it 
remains currentl y unknown as to whether there 
will be a benefit for patients being treated with 
MAS825 in this disease.
 Commercially Confidential Information
  Commercially Confidential Information
 Commercially Confidential Information
Commercially Confidential Information
Commercially Confidential Information
[COMPANY_001] Confidential Page 36of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
The patients enrolled in this study  will have COVID -19-associated pneumonia, impaired 
respi[INVESTIGATOR_847494] a significant risk of the 
development of ARDS requiring prolonged mechanical ventilation and ICU stay to maintain 
life. Currentl y, apart from supportive medical care that is of limited benefit in this population, 
there are no approved therapeutics targeting the underly ing inflammatory process to improve 
oxygenation, reverse respi[INVESTIGATOR_847495] -CoV -2 infection 
to improve the overall clinical outcome.
4.6.2 Potential risks to study  participant s
The risk to participants in this trial will be minimized by [CONTACT_50084], 
close clinical monitoring, frequent follow -up, minimal duration of the study , stoppi[INVESTIGATOR_847496] y data b y an independent DMC .
Commercially Confidential Information 
[COMPANY_001] Confidential Page 37of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
[IP_ADDRESS] Potential risk of Infection
As with any immune -modu lating compound, there is a theoretical risk of immune system 
impairment which might increase risk of infection in treated patients. However, MAS825 is not 
expected to elicit broad immune suppression, rather selectively  neutralize the pro inflammatory 
IL-1and free/bioactive IL-[ADDRESS_1178299]-study  
follow up. To mitigate potential risks of immune modulation and infection in this study , 
exclusion criteria include other immune suppressive treatments administered proximal to 
randomization, or concurrent use thereof. Patients are also excluded with known or suspected 
immunodeficiency  state or evidence of active, serious bacterial , fungal or viral infections (other 
than SARS -CoV2) .
[IP_ADDRESS] Potential risk of acute infusion and/or hy persensitivity  reactions
As with most biologic compounds, administration of MAS825 carries the risk of anaph ylaxis
and/or hypersensitivity -type reactions (see Section 16.1 ). MAS825 is administered as infusion 
over  to allow investigators discontinue treatment. In the event of such a reaction,
Investigators should consider study -specific criteria for treatment discontinua tion
(Section 9.1.1); and the patient should be treated with supportive care.
Recommendations 
regarding evaluation and treatment of adverse event sare provided in
Section 6.6.2 and IB section 7.
[IP_ADDRESS] Potential risk to women of child
-bearing potential
At this stage of development, MAS825 has not yet been assessed in reproductive toxicology 
studies, and all women of childbearing potential (WOCBP) must be informed that exposure to 
MAS825 may involve unknown risks to the fetus if pregnancy  were to occur. 
Commercially Confidential Information
   Commercially Confidential InformationCCI
[COMPANY_001] Confidential Page 38of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
4.[ADDRESS_1178300]. Additional samples may be 
required for safet y monitoring. 
Timings of blood sample collection are outlined in the assessment schedule ( Table 8-1 ).
See the 
Section [IP_ADDRESS] on the potential use of residual samples.
[ADDRESS_1178301] meet allof the following criteria:
1.Male and female patients aged ≥18years at screening
2.Signed Informed Consent Form (ICF) by [CONTACT_95271], or, when the
patient is not capable of giving consent, by [CONTACT_95272]/authorized representative (if
allowed according to local requirements)
3.Clinically  diagnosed with the SARS -CoV -2 virus by [CONTACT_940] (PCR) or
by [CONTACT_847533] 7 day sprior to randomization
Commercially Confidential Information
    Commercially Confidential Information
[COMPANY_001] Confidential Page 39of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
4.Hospi[INVESTIGATOR_21391] -19-induced pneumonia evidenced by [CONTACT_13190] x-ray, computed
tomograph y scan (CT scan) or magnetic resonance scan (MR scan) (taken within 5 days
prior to randomization)
5.Impaired respi[INVESTIGATOR_4806], defined as peripheral oxygen saturation (SpO 2) ≤93% on
room air or partial pressure of oxygen (PaO 2) / fraction of inspi[INVESTIGATOR_1401] (FiO 2)
<300 millimeter of mercury  (mmHg) at time of screening For cities located at altitudes
greater than 2500 m above sea level, these will be substituted with SpO 2<90% and
PaO 2/FiO 2<250 mmHg
6.Acute Physiolo gic Assessment and Chronic Health Evaluation (APACHE) II score of ≥10
at time of screening
7.CRP ≥20 mg/L  or ferritin level ≥600 μg/L at screening
8.Bodyweight between 45 kg and 145kg, inclusive, at screening
9.Ability to comply  with the study  protocol, in th e investigator's judgment
5.2 Exclusion criteria
Participants meeting anyof the following criteria are not eligible for inclusion in this study .
1.History  of hypersensitivity to the investigational treatment or their excipi[INVESTIGATOR_847497]
2.Suspected active or chronic bacterial (including Mycobacterium tuberculosis), fungal, viral,
or other infection (besides SARS -CoV -2)
3.In the opi[INVESTIGATOR_871], progression to death is imminent and inevitable within
the next [ADDRESS_1178302] 30 day s or 5 half -lives (whichever is the longer) for
immunomodulatory  therapeutic antibodies or prohibited drugs (see Section [IP_ADDRESS]) , with
the except ion of anti-viral therapi[INVESTIGATOR_847498] :
For COVID -
19 infection, ongoing corticosteroid treatment is permitted at doses as per
local SoC
For non -COVID -19 disorders, ongoing corticosteroid treatment is permitted 
at doses
up to and including predni solone 10 mg dail y or equivalent (see Section 6.2.1
Concomitant therap y)
7.Serum alanine transaminase (ALT) or aspartate transaminase (AST) >5 times upper limit
of normal detected within 24 hours at screening/baseline (accord ing to local laboratory
reference ranges) or other evidence of severe hepatic impairment (Child -Pugh Class C, see
Appendix 5 )
8.Absolute peripheral blood neutrophil count of ≤1000/mm3
9.Estimated GFR (eGFR) ≤30 mL /min/1.73m2(based on CKD -EPI [INVESTIGATOR_14420])
10.Pregnant or breastfeeding, or positive urine or serum pregnancy  test in a pre-dose
examination
[COMPANY_001] Confidential Page 40of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
11.Any serious medical condition or abnormality  of clinical laboratory  tests that, in the
investigator’s judgment, precludes the patient’s safe participation in and completion of the
study
12.Women ofchild- bearing potential, defined as all women physiologically  capable of
becoming pregnant, unless they agree to abstain from any sexual intercourse for a total of
29 day s after randomization (the 14 -day treatment period plus a 14-day follow -up period).
During the safet y follow up (from day 29 onwards), WOCBP should practice highly
effective contraception for4 months following treatment with MAS825, when it is predicted
that IL -18 and IL -1will not be neutralized by [CONTACT_847534]825 .
Women are considered post -menopausal and not of child bearing potential if they have had
12months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age
appropriate history  of vasomotor symptoms) or have had surgical bilateral oophorectomy
(with or without hysterectomy ), total hysterectomy  or bilateral tubal ligation at least six
weeks prior to randomization. In the case of oophorectomy  alone, only when the
reproductive status ofthe women has been confirmed by [CONTACT_847535].
13.Current participation in any other investigational trials
, with the exception of (not yet)
approved COVID -19 therapi[INVESTIGATOR_847499] (local) standard of care (also see
Section [IP_ADDRESS]. for Prohibited drugs ).
6 Treatment
6.1 Stud y treatment
Details on the requirements for storage and management of study treatment, and instructions to
be followed for prescribing/dispensing, and administering study  treatment are outlined in the 
pharmacy  manual.
6.1.[ADDRESS_1178303] (Table 6-1
).
Anunblin ded pharmacist or authorized designee is required to dispense the study  drug. 
Table 6-1 Investigational and control drug
Investigational/ 
Control Drug
(Name [CONTACT_6673])Pharmaceutical 
Dosage FormRoute of 
AdministrationSupply Type Sponsor (global 
or local)
MAS825 Intravenous use
    Commercially Confidential Information
Commercially Confidential InformationCommercially 
Confidential 
Information CCICommercially Confidential Information
[COMPANY_001] Confidential Page 41of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Investigational/ 
Control Drug
(Name [CONTACT_6673])Pharmaceutical 
Dosage FormRoute of 
AdministrationSupply Type Sponsor (global 
or local)
Matching Placebo Concentrate for 
solution for 
infusionIntravenous use Open label bulk 
supply; vialsSponsor (global)
6.1.2 Additional study treatments
Patients assigned to the MAS825 arm will receive single dose of MAS825  i.v. in 
addition to SoC, and patients assigned to the control arm will receive matching placebo in 
addition to SoC. Administered SoC in addition to study  treatment will be supplied by [CONTACT_68569]. No other investigational treatment beyond MAS825 is included in this study .
6.1.3 Treatment arms/group
Participants will be assigned at randomization to one of the following treatment arms/groups in 
a ratio of 1:1:
MAS825 i.v.
Matching placebo i.v.
6.2 Other treatment(s)
6.2.1 Concomitant therapy
All medications, procedures, and significant non-drug therapi[INVESTIGATOR_014] (including physical therapy  and 
blood transfusions) administered after the participant was enrolled into the study  mustbe 
recorded on the appropriate Case Report Forms (CRF).
Each concomitant drug must be individually  assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_18614] a participant or allowing a new medication to be started. If the participant is 
alread y enrolled, contact [CONTACT_6596] .
If participants are discharged from hospi[INVESTIGATOR_41337] 15, they must be told to notify  the 
treating ph ysician about any new medications he / she takes after receiving MAS825 treatment.
During the course of the study andalso prior to screening , participants may receive anti-viral 
therapi[INVESTIGATOR_014] (e.g., hydroxy chloroquine, chloroquine, remdesivir, faripi[INVESTIGATOR_847492], ritonavir, lopi[INVESTIGATOR_847500] -CoV -2 antibodies)
,intravenous, oral 
or inhaled corticosteroids (e.g. prednisolone, dexamethasone, methy lprednisolone ), antibiotics, 
anti-coagulants and other agents /treatments where these form part of SoC for the treatment of 
COVID -19 at their participating center (per medical judgement) .
Patients are permitted to receive low-dose corticosteroids (up to a maximum of 10 mg/da y 
predni solone equivalent) for the treatment of non-COVID -19 disorders. Immunomodulatory 
(topi[INVESTIGATOR_3398]) use for asthma and atopic dermatitis or corticosteroid use (per medical 
judgement) are not restricted.
CCICCI
[COMPANY_001] Confidential Page 42of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Whilst the protocol defines experimental immunomodu latory  treatments including but not 
limited to anti-IL-6 monoclonal antibodies as prohibited ( Section [IP_ADDRESS]), patients with 
significantl y deteriorating clinical status after MAS825 or placebo may still receive such 
therapi[INVESTIGATOR_847501] y outweighs the risks. However, patients having receiv edexperimental 
immunomodulatory  therapi[INVESTIGATOR_847502]825 or placebo should 
remain in the study  and the Investigator should continue collecting data on outcomes through 
the study  visit schedule.
[IP_ADDRESS] Prohibited drugs
The following medications are prohibited: 
Experimental immunomodulatory  therapi[INVESTIGATOR_847503] -19, including, but not 
limited to canakinumab, anakinra and other anti-IL-1 antibodies, tocilizumab , sarilumab and 
other anti-IL-6 antibodies, ruxolitinib and other JAK inhibitors, eculizumab and other 
complement inhibitors (investigat ional or marketed) .
Concomitant use of biologics including abatacept, rilonacept, rituximab and any other biologics 
(investigational or marketed) and TNF inhibitors including etanercept, adalimumab, infliximab 
and/or other TNF inhibitors (investigational or mar keted).
All investigational medications being used in an investigational trial.
[IP_ADDRESS] Permitted concomitant therapy  requiring caution and/or action
Use of oral, injected or implanted hormonal methods of contraception are allowed while on 
MAS825.
6.3 Participant numbering, treatment assignment, randomization
6.3.1 Participant numbering
Each participant is identified in the study  by a Participant Number (Participant No.), that is 
assigned when the participant is enrolled for screening 
and is retained for the participant 
throughout his/her participation in the trial. A new Participant No. will be assigned at every  
subsequent enrollment if the participant is re-screened. The Participant No. consists of the 
Center Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential 
participant number suffixed to it, so that each participant’s participation is numbered uniquely  
across the entire database. Upon signing the informed consent form, the participant is assigned 
to the next sequential Participant No. available.
A new I CF will need to be signed if the investigator chooses to re -screen the participant after a 
participant has screen failed, and the participant will be assigned a new Participant No.
6.3.2 Treatment assignment, randomization
At randomization visit, all eligible participants will be randomized via Interactive Response 
Technology  (IRT) to one of the treatment arms. The investigator or his/her delegate will contact 
[CONTACT_6608]/exclusion criteria. The IRT 
[COMPANY_001] Confidential Page 43of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
will assign a randomization number to the participant, which will be used to link the participant 
to a treatment arm.
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and concealed from participants and investigator staff. 
Aparticipant randomization list will be produced by [CONTACT_6609] a validated system 
that automates the random assignment of participant numbers to randomization numbers. 
These randomization numbers are linked to the different treatment arms. A randomization list 
will be produced by [CONTACT_847536]  (GCS) using 
a validated system that automates the random assignment of treatment arms to randomizat ion 
numbers in the specified ratio.
Randomization will be stratified b y:
age ( ≤65y ears, >65 years)
administration of any  anti-viral therap y (e.g., h ydrox ychloroquine, chloroquine,
convalescent plasma, remdesivir, faripi[INVESTIGATOR_847492], ritonavir, lopi[INVESTIGATOR_054]) as SoC (y es / no)
presence of ≥1 of the following comorbidities: diabetes, hy pertension, cardiovascular
disease, chronic lung disease (y es / no)
The randomization scheme for participants will be reviewed and approved by  a member of the 
Randomization Office.
6.4 Treatment blinding
This is a blinded study . Participants and investigators will remain blinded to study  treatment 
throughout the study, except where indicated below.
Participants, investigator staff, persons performing the assessments, and the clinical trial team 
(CTT) will remain blind to the identity  of the treatment from the time of randomization until 
end of study  visit appl ying the following rules:
Randomization data are kept strictly confidential until the time of unblinding .
Unblinding will occur in the case of participant emergencies and at the conclusion of the
study .
Unblinding of the CTT members may  occur for the purpose of periodic review of the
safet y data.
Unblinded results from the planned interim analysis after all participants have completed
the Day  29 visit can be shared with the participants and site staff, if deemed appropriate.
The identity  of the treatments will be concealed by [CONTACT_50090], labeling, schedule of administration, appearance, a nd odor.
Site staff
With the exception of any unblinded site staff identified below, all site staff (including study 
investigator and study  nurse) will be blinded to study treatment throughout the study .
Unblinding a single participant at site for safet y reasons (necessary  for participant management) 
will occur via an emergency  system in place at the site.
[COMPANY_001] Confidential Page 44of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Drug product will be supplied in bulk, so an unblinded pharmacist who is independent of the 
study  team will be required in order to maintain the blind. This unblinded pharmacist at the site 
will be notified by  [CONTACT_847537] a participants randomized and to which treatment arm, 
which will then enable them to prepare the stud y drug. Appropria te measures must be taken b y 
the unblinded pharmacist to ensure that the treatment assignments are concealed from the rest 
of the site staff.
Sponsor staff
The following unblinded sponsor roles are required for this study  amend as appropriate:
Unblinded field monitor(s)
Unblinded clinical staff managing drug re -supply  to site
Unblinded sample anal yst(s)
The unblinded field monitors are required to review drug accountability  and allocation at site. 
The unblinded monitors are not provided with a randomization listdirectly  but will be unblinded 
through review of source documentation compi[INVESTIGATOR_847504], which details 
treatment allocation to individual participants. 
Sponsor clinical staff are required to assist in the management and re -supply  of in vestigational 
drug product. These individuals are not provided with randomization lists directly , but may  be 
unblinded through communication of drug re -supply  needs via the unblinded site pharmacists.
The sample analysts will receive a copy of the randomiz ation schedule (via request to the 
Randomization Office), to facilitate analysis of the samples. The sample analy sts will provide 
the sample data to the study  team under blinded conditions unless otherwise allowed.
The study  statistician will be able to access the randomization list for interim analyses and is 
allowed to share unblinded information with the rest of the clinical team as appropriate for 
internal decision purposes, as outlined in Table 6-2. For example, unblinded summaries and 
unblinded individual data can be shared with the team for all interim anal yses.
Study  programmers and other personnel involved in study  data anal ysis 
are allowed to access treatment assignment information for the purpose of conducting interim 
analyses.
The clinical trial team is allowed to share unblinded results with other sponsor staff 
(e.g. decision boards) as required for internal decision making on the stud y or the project at the 
time of interim analyses while the study  is ongoing. The results from the planned interim 
analysis after all participants have completed their Day 29 visit (or discontinued from the stud y 
earlier) can be shared more broadl y including with participants and site staff, if deemed 
appropriate. If this occurs, then all roles should be considered unblinded from this time points 
onwards. Otherwise, following final database lock all roles may  be considered unblinded.
All unblinded personnel will otherwise keep randomization data or information that could 
unblind other study  team members confidential and secure except as described above.
Commercially Confidential InformationCCI
 CCI
[COMPANY_001] Confidential Page 45of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Table 6-[ADDRESS_1178304] generatedTreatment 
allocation & 
dosingSafety  event 
(single participant 
unblinded)Interim a nalysis
Participants B B UI B*
Site staff B B UI B*
Unblinded site staff e.g. 
pharmacy staff (specify)UI UI UI UI
Global Clinical Supply 
and Randomization 
OfficeUI UI UI UI
Unblinded sponsor staff 
e.g. for study treatment
re-supply, unblinded
monitor(s), sample
analyst(s)UI UI UI UI
Unblinded 
Pharmacovigilance 
sponsor staffUI UI UI UI
Statistician/statistical 
programmer/ data 
analysts (e.g. 
)B B UI UI
Independent 
committees used for 
assessing interim 
results, if required (e.g. 
DMC)B B UI UI
All other sponsor staff 
not identified above 
(i.e. trial team, project 
team, management & 
decision boards, 
support functions)B B UI UI
UI: Allowed to be unblinded on individual participant level
B: Remains blinded
NA: Not applicable to this study
*Unblinded results from the planned interim analysis after all subjects have completed their Day 29 visit (or
discontinued earlier) can be shared with participants and site staff, if deemed appropriate. Results from any other
interim analysis prior to the Day 29 visit should not be shared with participants and site staff.
6.5 Dose escalation and dose modification
Investigational or other study  treatment dose adjustments and/or interruptions are not permitted.
6.6 Additional treatment guidance
6.6.1 Treatment compliance
As dosing will be completed at the study  site, assessment of compliance is not applicable. 
Allstudy  treatment administered will be recorded on the Study Treatment eCRF. Serum levels 
of MAS825 will be determined at pre-specified timepoints as measures of treatment compliance.  
CCI
[COMPANY_001] Confidential Page 46of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
in all participants treated with MAS825, as detailed in “Assessment Schedule” in 
Table 8-[ADDRESS_1178305] be recorded on the approp riate CRF.
Treatment of infection
In the event of an infection, Investigators should consider early treatment with specific 
antimicrobial therap y based on clinical diagnosis or suspi[INVESTIGATOR_123221] (e.g., anti -viral treatment 
for herpes simplex or zoster) in consultation with infectious disease experts, as appropriate.
Treatment of acute infusion and/or hy persensitivity  reactions
As with most biologic compounds,  administration of MAS825 carries the risk of
anaph ylaxis and/or hypersensitivity -type reactions (see Section 16.1). In the event of such a
reaction, Investigators should consider study -specific criteria for treatment discontinuation
(Section 9.1.1), and the patient should be treated with antihistamines and glucocorticoids.
Depending on severit y, subjects may also require supplemental oxygen, volume expansion,
catecholamines and transfer to an intensive care setting. Plasmapheresis to decrease the
systemic concentration of MAS825 may be considered dependent on the patient’s condition.
Subjects should be observed for at least four hours after resolution of signs and s ymptoms, and
those who have experienced severe infusion reactions should b e closel y observed for [ADDRESS_1178306] has recovered. The use of 
plasmapheresis may be considered to facilitate more rapid elimination of MAS825 from the 
peripheral circulation in the case of overdose.
At present there is insufficient information to provide specific recommendations regarding 
treatment of other potential adverse events (AEs) in this patient population. Acute kidney  injury  
is common in patients with severe COVID -19. Treatment is supportive, with the institution of 
renal replacement therapy where this is indicated.
Medication used to treat adverse events (AEs) must be recorded on the appropriate CRF.
 CCI
[COMPANY_001] Confidential Page 47of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
6.6.[ADDRESS_1178307] often, study  treatment discont inuation and knowledge of the possible 
treatment assignments are sufficient to treat a study  participant who presents with an emergency  
condition. Emergency  treatment code breaks are performed using the IRT. When the 
investigator contacts the system to break a treatment code for a participant, he/she must provide 
the requested participant identify ing information and confirm the necessity  to break the 
treatment code for the participant. The investigator will then receive details of the 
investigational drug treatment for the specified participant and a fax or email confirming this 
information. The system will automatically  inform the [COMPANY_001] monitor for the site and the 
study  team that the code has been broken.
It is the investigator’s responsibility  to ensur e that there is a dependable procedure in place to 
allow access to the IRT at any  time in case of emergency . The investigator will provide:
protocol number
name (if available)
participant number
In addition, oral and written information to the participant must be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency, or when he/she is unavailable, to ensure that un -blinding 
can be performed at an y time.
6.[ADDRESS_1178308] and dispensation are 
provided in Pharmacy  Manual.
6.7.1 Handling of stu dy treatment and additional treatment
[IP_ADDRESS] Handling of study  treatment
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y and kept in a secured location to which only the investigator and designated
site personnel have access. Upon receipt, all study  treatment must be stored according to the 
instructions specified select as applicable on the labels
Clinical supplies are to be dispensed only in accordance with the protocol. Technical complaints 
are to be reported to the respective [COMPANY_001] Country  Organization (CO) Quality  Assurance.
Medication labels will be in the local language and comply with the legal requirements of each 
country . They  will include storage conditions for the study  treatment but no information about 
the participant except for the medication number.
[COMPANY_001] Confidential Page 48of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability log. Monitoring of drug accountability  will be performed by  
[CONTACT_30798]. 
At the conclusion of the study , and as appropriate during the course of the study , the investigator 
will return all unused study  treatment, packaging, drug labels, and a copy of thecompleted drug 
accountability  log to the [COMPANY_001] monitor or to the [COMPANY_001] address provided in the 
investigator folder at each site.
[IP_ADDRESS] Handling of additional treatment
Not applicable
6.7.2 Instruction for prescribing and taking study treatment
Please refer to Pharmacy  Manual. 
Table 6-3 Dose and treatment schedule
Investigational / Control Drug
(Name [CONTACT_131377])Dose Frequency and/or Regimen
MAS825 Day 1 by i.v. infusion
Placebo Day 1 by i.v. infusion
7 Informed consent procedures
Eligible participants may only be included in the study  after providing (witnessed, where 
required by [CONTACT_6617]), Institutional Review Board (IRB) / Independent Ethics 
Committee (I EC)-approved informed consent.
If applicable, in cases where the participant's representative(s) gives consent (if allowed 
according to local requirements), the participant must be informed about the study to the extent 
possible given his/her understanding. If the participant is or becomes capable of doing so, 
he/she must indicate agreement by  [CONTACT_847538]. The consenting process for all study participants will be performed according to the 
applicable local regulations and described intheICF.
Informed consent must be obtained before conducting any study-specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
docume nted in the participant source documents.
[COMPANY_001] will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory  requirements and is considered 
appropriate for this study . Anychanges to the proposed consent form suggested by [CONTACT_49413] I RB/IEC.
CCI CCI
[COMPANY_001] Confidential Page 49of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB). This information will be included in the 
participant informed consent and should be discussed with the participant during the study  as 
needed. Any new information regarding the safety  profile of the investigational drug that is 
identified between IB updates will be communicated as appropriate, for example, via an 
investigator notification or an aggregate safet y finding. New information might require an 
update to the informed consent and then must be discussed with the participant.
The following inform ed consents are included in this study :
Main study  consent, which also includes:
As appl icable, Pregnancy Outcomes Reporting Consent for female participants who took
study  treatment

As applicable, an optional Home Nursing visit consent for all participants to allow for 
home nursing visit if a site visit is not possible
Women of child- bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participa te in the study they  must adhere to the contraception requirements.
A copy  of the approved version of all consent forms must be provided to [COMPANY_001] after IRB/IEC 
approval.
Commercially Confidential Information
Commercially Confidential InformationCommercially Confidential Information
[COMPANY_001] Confidential Page 50of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
8 Visit schedule and assessments
The Assessment Schedule (Table 8-1) lists all assessments when they are performed. All data obtained from these assessments must be 
supported in the participant ’s source documentation.
Participants should be seen for all visits/assessments as outlined in the assessment schedule (Table 8 -1)or as close to the designated day/time 
as possible. Missed or rescheduled visits should not lead to automatic discontinuation. Participants who prematurel y disconti nue the study  for 
any reason should be scheduled for a visit as soon as possible, at which time all of the assessments listed for the final visit will be performed. 
If participant is prematurely  discontinued from the study  at any visit before Day 15, then assessments of Day 15visit should be performed ,
andif participant is prematurely  discontinued at any visit after Day 15and before Day 127, then assessments of Day 127visit should be 
performed. 
Table 8
-1 Assessment schedu le 
Period Screening / 
Baseline / 
TreatmentTreatment2 Post -Treatment Follow -up EOS
Visit Name [CONTACT_6674] / 
Baseline / 
Treatment14Observation Discharge3 Follow -up4
(if hospi[INVESTIGATOR_847505] 2 days; 
if discharged only telephone 
call on Day 29)Safety 
follow -
up4EOS/Safety 
Follow up4
Days -1 to 1 2 4 6 8 10 12 14 15 17, 19, 21, 23, 
25, 2729 
(-1/+3 
days)455
(+/-7
days)127 (+/ - 7
days)5
Domiciled (as required) X X X X X X X X X X X
Inclusion / Exclusion criteria X
Demography X
Medical history/current medical conditions X
Presence SARS -CoV-2 virus / viral load5X
Chest X -ray (CXR), CT or MR scan per local SoC5X X12
Randomization (IRT) X
Physical examination13S S S S S S
Vital signs6X X X X X X X X X X X X X
CCI
CCI
[COMPANY_001] Confidential Page 51of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Period Screening / 
Baseline / 
TreatmentTreatment2 Post -Treatment Follow -up EOS
Visit Name [CONTACT_6674] / 
Baseline / 
Treatment14Observation Discharge3 Follow -up4
(if hospi[INVESTIGATOR_847505] 2 days; 
if discharged only telephone 
call on Day 29)Safety 
follow -
up4EOS/Safety 
Follow up4
Days -1 to 1 2 4 6 8 10 12 14 15 17, 19, 21, 23, 
25, 2729 
(-1/+3 
days)455
(+/-7
days)127 (+/ - 7
days)5
Respi[INVESTIGATOR_82219] (spont. breathing, FiO 2, ventilator 
parameters, ECMO), fluid balance, need for CRRTX X X X X X X X X X X X X
APACHE II, X X X X X X X X X X X X X
Clinical Status Evaluation with 9 -category ordinal scale X X X X X X X X X X X X X
Weight and Height7X X X
ECG evaluation (local)14X X
Pregnancy test –urine/serum (local lab)9X X X
Blood chemistry including CRP, Ferritin, LDH, ANC, D -
dimer ,troponin and BNP (local lab)8 X X X X X X X X X X X X X
Hematology (local lab)8X X X X X X X X X X X X X
Coagulation Panel8X X X X X X X X X X X X X
Drug administration record11X 
Concomitant medications/Therapi[INVESTIGATOR_847506]/serious adverse events X
Safety Follow up Call X X X X
Study completion information X
X = assessment to be recorded in the clinical database or received electronically  from a vendor
S = assessment to be recorded in the source documentation only
1.Informed consent must be signed prior to any study -related procedure. 
2.Study treatment may start immediately after obtaining the screening/baseline measurements and confirming eligibility.  Day 15 visit should be performed for all patients.
3.If patient is discharged prior to Day 15 (early discharge), then assessments on the day of discharge should be performed according to the s chedule listed under Day 15 and patient should return to the site for the 
Day 15 assessment , with a time window of +2 days (if hosp ital visit is not possible, then home nursing is allowed on day 15 (with a time window of +2 days) that should include all possible assessments including 
oxygen saturation with portable monitors ). In case, home nursing is not possible, patients will be con tacted by [CONTACT_847539] 15 (with a time window of +2 days) , where respi[INVESTIGATOR_91386], performance status, 
adverse events, concomitant medication and medical and surgical history will be obtained). No time window for Day 15 is allowed if the patient isnot discharged prior to day 15.
Commercially Confidential Information CCI
Commercially Confidential Information 
[COMPANY_001] Confidential Page 52of 91
Amended Protocol Version 01 (Clean ) Proto col No. CMAS825F12201
Period Screening / 
Baseline / 
TreatmentTreatment2 Post -Treatment Follow -up EOS
Visit Name [CONTACT_6674] / 
Baseline / 
Treatment14Observation Discharge3 Follow -up4
(if hospi[INVESTIGATOR_847505] 2 days; 
if discharged only telephone 
call on Day 29)Safety 
follow -
up4EOS/Safety 
Follow up4
Days -1 to 1 2 4 6 8 10 12 14 15 17, 19, 21, 23, 
25, 2729 
(-1/+3 
days)455
(+/-7
days)127 (+/ - 7
days)5
4.f patient is discharged after Day 15 and prior to Day 127 (discharge), then assessments on the day of discharge should be per formed according to the schedule listed under Day 127. Furthermore, visits at Days 29, 
45 and 127 should be conducted via phone for patients who were discharged prior to the visit (see footnote 3 for assessments to be obtai ned on the phone). Visits between day of discharge and Day [ADDRESS_1178309] or MRI scan within 5 days prior to random ization may  be used for 
eligibility. 
6.Vital signs include heart rate, respi[INVESTIGATOR_697] (if not on mechanical ventilation), systolic and diastolic blood pressure an d body temperature. If possible, v ital signs should be recorded at the same time at every visit
for a patient (i.e. morning, afternoon or evening) and upon significant clinical changes. Oxygen saturation (if not on mechanical ventilation) orPaO 2/FiO 2should be measured at the same time as the vital sign s
measurements. Ifpatient is rec eiving supplemental oxygen (not on invasive ventilation) then oxygen flow rate and/or FiO2 and oxygen saturation to be collected.
7.If not possible to measure height, it can be reported by [CONTACT_102]. Height will be measured only at screening/baseline/trea tment vi sit.
8.Hematology, blood chemistry and coagulation panel including CRP, Ferritin, LDH, ANC, D -dimer, troponin and BNP should be measured by [CONTACT_12082]. 
9.Pregnancy test applicable only for females of childbearing potential; serum pregnancy test (se rum hCG) will be performed by [CONTACT_12117]. For enrollment a negative urine test is sufficient
10.
11.For the treatment day, all assessments should be performed pre -dose.
12.Chest X -ray, CT or MRI scan at Day 15 will be performed and reported only if available and performed according to SoC .The same method should be used at Day 15 (or on day of discharge if prior to Day 15) as 
was used at screening.
13.A complete physical examination will be performed at baseline . Fortheremaining time points, a targeted physical examination, as per investigator discretion, may be performed.
14.All procedures performed as part of local standard of care during this hospi[INVESTIGATOR_059], may be used for screening/baseline assessments provided that they were performed up to 24 hours prior to ICF signature. ECG
examination conducted during this 24h window will be accepted as long as the same diagnostic method is used throughout the study.
15.Urine output to be measured as per local SoC.
  Commercially Confidential Information 
[COMPANY_001] Confidential Page 53of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
8.1 Screening
It is permissible to re -screen a participant once if s/he fails the initial screening.
In the case where a safety  laboratory  assessment at screening /baseline is outside of the range 
specified in the exclusion criteria, the assessment may be repeated once prior to randomization. 
If the repeat value remains outside of the specifie d ranges, the participant must be excluded 
from the study .
8.1.1 Information to be collected on screening failures
Participants who sign an informed consent form and subsequentl y found to be ineligible prior 
to randomization will be considered a screen failure. The reason f or screen failure should be 
recorded on the appropriate CRF. The demographic information, informed consent, and 
Inclusion/Exclusion pages must also be completed for screen failure participants. No other data 
will be entered into the clinical database for participants who are screen failures, unless the 
participant experienced a serious adverse event during the screening phase (see Section 10.1.3
for reporting details). If the participant fails to be ra ndomized, th e IRT must be notified within 
2 day s of the screen fail that the participant was not randomized.
Participants who are randomized and fail to start treatment, e.g. participants randomized in error, 
will be considered an early  terminator. The rea son for earl y termination should be recorded on 
the appropriate Case Report Form.
8.2 Participant demographics/other baseline characteristics
Country -specific regulations should be considered for the collection of demographic and 
baseline characteristics in al ignment with CRF.
Participant race and ethnicity  are collected and analyzed to identify  variations in safet y or 
efficacy  due to these factors as well as to assess the diversit y of the study  population as required 
by [CONTACT_33821]
8.2.1 Demographic information
Demographic data to be collected at screening on all participants include: year of birth or age, 
gender, race, ethnicity  and child -bearing potential (for females onl y).
Any relevant medical history  including date of onset of COVID -19 disease sy mptoms, date of 
diagnosi s of COVID -19 disease protocol solicited medical history , and/or current medical 
conditions before obtaining informed consent will be recorded in the Medical History  CRF. 
Significant findings that are observed after the participant has provided informed consent and 
that meet the definition of an AE must also be recorded in the AE CRF. Whenever possible, 
diagnoses and not s ymptoms will be recorded.
Investigators will have the discretion to record abnormal test findings on the medical history 
CRF whenever in their judgment, the test abnormality  occurred prior to the informed consent 
signature.
[COMPANY_001] Confidential Page 54of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
8.2.2 Prior and concomitant medications
Relevant prior and concomitant medications will be captured at the screening visit. Any changes 
to the ongoing medications or any new c oncomitant medications will be recorded in CRF on an 
ongoing basis throughout study  participation .
8.3 Efficacy
Samples will be collected at the timepoints defined in the Assessment Schedule (Table 8-1) and 
will be obta ined and evaluated in all participants. 
8.3.1 Vital signs and oxygen saturation and use
Vital sign measurements include respi[INVESTIGATOR_2842], pulse rate, systolic and diastolic blood 
pressure, and body  temperature. If possible, vital signs should be recorded at thesame time at 
every  visitfor a patient (i.e. morning, afternoon or evening) and upon significant clinical 
changes.
Peripheral oxygen saturation on room air should also be measured at the same time as the vitals, 
if not on supplemental oxygen. If patient is receiving supplemental oxygen (not on invasive 
ventilation), then oxygen flow rate (L/min) and/or fraction of inspi[INVESTIGATOR_1401] (FiO 2)and 
oxygen saturation should be recorded. PaO 2/FiO 2should be recorded as needed (see Appendix
5forguidance on estimation of PaO2/FiO2 ).
8.3.2 APAC HE II severity  of disease score
APACHE II (Acute Physiology  And Chronic Health Evaluation) records various parameters 
grouped in vital signs, oxygenation, chemistry  and hematology ; in addition age and Glasgow 
Coma score is par t of the APACHE II score ( Knaus et al 1985 ) (Appendix 4 ). The worst value 
for each parameter in the last 24 hours will be entered in the CRF ,with parameters recorded, if 
possible, at the same time at every  visitfor a patient (i.e. morning, afternoon or evening) and 
upon significant clinical changes . Parameters for APACHE II will be recorded at 
screening/baseline, Day 2 and then every  other day until Day 29 for hospi[INVESTIGATOR_847507]. The score will be recorded onl y for the screening/baseline visit 
in the CRF.
Mean arterial pressure (MAP) may either be directly  measured or calculated from the diastolic 
and sy stolic blood pressure ( per medical judgement ). 
For oxygenation variables, where patients have an arterial line sited an arterial blood sample 
should be used. Inpatients, without an arterial line sited should have either an arterial, or 
equivalent measurement (eg capi[INVESTIGATOR_21274]). In the case, where an arterial sample is not 
indicated or feasible clinically , a venous blood gas sample scan be used and the PaO 2estimated
(per medical judgement , see Table 16-4 for guidance on estimation of PaO2 ).For a given patien
t
the same methodology to obtain theAPACHE II parameter sshould utilized throughout the 
study  where clinically  feasible /indicated .
[COMPANY_001] Confidential Page 55of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
8.3.3 Clinical status (9 -point ordinal scale)
Assessment of clinical status using a 9-point ordinal scale (WHO 2020) will be recorded at 
baseline, Day 2 and then every  other day until Day 29 for hospi[INVESTIGATOR_9643] (Appendix 2).  
If a patient is discharged from the hospi[INVESTIGATOR_307], the assessment will be made by [CONTACT_847540] 8-1. Each day, the patient’s status from theprevious calendar dayis 
reviewed; the ordinal score isassigned based on thepatient’s worst status from the previous 
day. This score (based on the review ofthe previous day)will be recorded (i.e. on Day 3, the 
Day [ADDRESS_1178310] score is 
recorded as the score for Day 2).In addition, on Day 127or the Day of discharge, clinical status 
on Day  127 or the Day  of discharge should be recorded .
8.3.4 CRP and Ferr
itin
Blood samples will be collected according to the Assessment Schedule ( Table 8 -1), performed 
locally  and recorded in the CRF .
8.3.5 Appropriateness of efficacy  assessments
The efficacy  endpoints selected for this study  are clinically  relevant and in keepi[INVESTIGATOR_847508] -19 pneumonia ( WHO 2020 ).
[COMPANY_001] Confidential Page 56of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
8.4 Safet y
Safety  assessments are specified below with the assessment schedule detailing when each 
assessment is to be performed.
For details on AE collection and reporting, refer to AE Section 10.1.1.
Assessment Specification
Physical examination A com plete physical examination will include the examination of general 
appearance, skin, neck (including thyroid), eyes, ears, nose, throat, 
lungs, heart, abdomen, back, lymph nodes, extremities, vascular, and 
neurological. If indicated based on medical histor y and/or symptoms, 
rectal, external genitalia, breast, and pelvic exams will be performed
Information for all physical examinations must be included in the source 
documentation at the study  site. Clinical ly relevant findings that are 
present prior to signing informed consent must be recorded on the 
appropriate CRF that captures medical histor y. Significant findings made 
after signing informed consent which meet the definition of an Adverse 
Event must be re corded as an adverse event.
Vital signs Vital signs will include the collection of rectal, otic or oral body 
temperature (recorded in °C), blood pressure (BP) and pulse 
measurements.
Peripheral oxygen saturation on room air should also be measured at 
the same time as the vitals. For participants requiring supplemental 
oxygen, the ox ygen flow rate (L/min) and/or FiO2 should be recorded.
Height and weightHeight in centimeters (cm) and body weight (to the nearest 0.1 kilogram 
(kg) in indoor clothing, but without shoes) will be measured as specified 
in Table [ADDRESS_1178311] be recorded as either medical history /current medical 
conditions or adverse events as appropriate.
Safety  laboratory  evaluations will be performed by  [CONTACT_12082] .
[COMPANY_001] Confidential Page 57of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Special clinical laboratory  evaluations
All abnormal lab results must be evaluated for criteria defining an adverse event and reported 
as such if the criteria are met. For those lab adverse events, repeated evaluations are mandatory 
until normalization of the result(s) or until the result is no longer considered to be clinically 
significant.
Safety  clinical laboratory  tests will be performed locally  (see Table 8-2) and recorded in the 
CRF.
Table 8-2 Clinical laboratory  tests (local)
Clinically  notable laboratory  findings are defined in Appendix [ADDRESS_1178312] Name
[CONTACT_157131], Hemoglobin, Platelets, Red blood cells, White blood cells, 
Differential (Basophils, Eosinophils, Lymphocytes, Monocytes, 
Neutrophils, Bands
Chemistry Albumin (ALB), Alkaline phosphatase, ALT , AST , Gamma -glutam yl-
transferase (GGT), Lactate dehydrogenase (LDH) , Bicarbonate, 
Calcium, Magnesium, Phosphorus, Chloride, Sodium, Potassium, 
Creatinine, Creatine kinase ,Total Bilirubin (TBL), Total Protein, 
Trigly cerides, Blood Urea Nitrogen (BUN) or Urea, Uric Acid, Amylase, 
Lipase, Glucose (non-fasting), CRP, Ferritin, D-dimer, Troponin, Brain 
Natriuretic Peptide (BNP)
Coagulation * Prothrombin time (PT), International normalized ratio [INR]), Partial 
thromboplastin time (PTT), Activated partial thromboplastin time (APTT)
Pregnancy Test Serum / Urine pregnanc y test (refer to 'Pregnanc y and assessments of 
fertility' Section 8.4. 5)
*Coagulation assessment should include only those tests routinely performed according to local
standard of care.
8.4.2 Physical examination
A complete physical examination will be performed according to the Assessment Schedule 
(Table 8-1).
8.4.3 Height and weight
Height in centimeters (cm) and body  weight (to the nearest 0.1 kilogram (kg) in indoor clothing, 
but without shoes) will be measured as specified in Table 8-1.
If height cannot be measured, the value reported by  [CONTACT_31823] t will be entered in the CRF.
8.4.4 Electrocardiogram (ECG)
ECG assessments will be taken locall y. 
ECGs must be recorded after [ADDRESS_1178313].
The Fridericia QT correction formula (QTcF) must be used for clinical decisions.
[COMPANY_001] Confidential Page 58of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Single ECGs are to be collected with ECG machines available at the site. Single ECGs are 
collected, and results are entered into the appropriate eCRF page. The original ECGs on non-
heat-sensitive paper, appropriatel y signed, must be collected and archived at the study site.
ECG examination conducted within the 24h time window prior to screening will be accepted as 
long as the same diagnostic method is used throughout the study .
Each ECG tracing must be labeled with study  number, participant initials, participant number, 
date and time, and filed in the study  site source documents. 
Clinically  significant abnormalities must be recorded on the relevant section of the medical 
history /Current medical conditions/AE eCRF as appropriate. If necessary , a cardiologist may 
be consulted.
8.4.[ADDRESS_1178314] on 
Day 15, Day 29, monthly  thereafter until end of study , and should inform study  site/investigator
if they  become pregnant. 
Assessments of fertility
Medical documentation of oophorectom y, hysterectomy , or tubal ligation must be retained as 
source documents. Subsequent hormone level assessment to confirm the woman is not of child-
bearing potential must also be available as source documentation in the f ollowing cases:
1.Surgical bilateral oophorectomy  without a hy sterectomy
2.Reported 12 months of natural (spontaneous) amenorrhea with an appropriate clinical
profile.
8.4.[ADDRESS_1178315] X -ray (CXR) or chest CT or MRscan, will be performed as per local standard 
practice to diagnose pneumonia; except for those who have had a valid test done within 5 day s
of randomization. The radiological examination performed at Day 15 (or on day of discharge 
if prior to Day  15) willbe collected onl y if performed according to local SoC and if visit at the 
hospi[INVESTIGATOR_847509]. The same method should be used at Day  15 (or on da y of discharge if prior 
to Day  15) as was used at screening.
Additional assessments may  be performed, as needed.
Results from chest X -ray, CT scan or MR scan will be recorded in the CRF.
8.4.7 Appropriateness of safety  measurements
The safet y assessments selected are appropriate for this protocol which utilizes a compound 
which has not previousl y been used in a p atient population and where the safety profile has not 
[COMPANY_001] Confidential Page 59of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
therefore been established. The assessments are relevant to the critical care setting and will 
enable determination of both safet y and therapeutic response in this setting.
8.5 Additional assessments
      Commercially Confidential Information 
[COMPANY_001] Confidential Page 60of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Commercially Confidential Information 
[COMPANY_001] Confidential Page 61of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
9 Study  discontinuation and completion
9.1 Discontinuation and comp letion
9.1.1 Study treatment discontinuation and study discontinuation
This study  involves single i.v. infusion of an approximate duration of , and therefore 
the infusion can be interrupted if necessary. In case the clinical setting requires it (e .g.long i.v. 
line),
Discontinuation of study treatment for a participant occurs when study  treatment is stopped 
earlier than the protocol planned duration. Discontinuation of study  treatment can be decided 
by [CONTACT_6633]. 
Study  treatment must be discontinued under the following circumstances: 
Participant /guardian decision - participant s may  choose to discontinue study  treatment for
any reason at any  time. The investigator believes that continuation would negativel y
impact the safet y of the participant or the risk/benefit ratio of trial participa tion
Moderate or severe h ypersensitivity  reaction occurs, including an y of the following:
anaph ylaxis ( Section 16.1), fever, chills, urticaria, dy spnea, headache, my algia,
hypotension. Immediate discontinuation of study  treatment and initiation of appropriate
medical treatment is required in such cases.
Moderate or severe infusion -related reaction to study  drug.
Any protocol deviation or situation that results in a significant risk to the participant ’s
safet y.
Commercially Confidential Information 
CCI
Commercially Confidential Information 
[COMPANY_001] Confidential Page 62of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
The appropr iate personnel from the site and [COMPANY_001] will assess whether investigational drug 
treatment should be discontinued for any participant whose treatment code has been broken 
inadvertentl y for an y reason. 
If discontinuation of study  treatment occurs, invest igator must determine the primary  reason for 
the participant ’s premature discontinuation of study  treatment and record this information on 
the Dosage Administration CRF. 
Participants who discontinue study  treatment or who decide they do not wish to partic ipate in 
the study  further should NOT be considered withdrawn from the study  UNLESS they withdraw 
their consent (see 'Withdrawal of Informed Consent' Section 9.1.2). Where possible, they should 
return for the assessments in dicated in the Assessment Schedule. If they  fail to return for these 
assessments for unknown reasons, every  effort (e.g.,telephone, e-mail, and letter) should be 
made to contact [CONTACT_2299]/pre -designated contact [CONTACT_847541] 'Lost to follow -up' 
Section 9.1.3. This contact [CONTACT_37283] y be done according to the study visit schedule.
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain 
regular telephone contact [CONTACT_6635], or with a person pre-designated by [CONTACT_2299]. 
This telephone contact [CONTACT_37283] y be done according to the stud y visit schedule.
After study  treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should be collected at clinic visits or via telephone/email contact:
New / concomitant treatments
Adverse Events / Serious Adverse Events
The investigator must also contact [CONTACT_6637]’s discontinuation from 
study  treatment.
9.1.2
Withdrawal of i nformed consent
Participants may  voluntarily  withdraw consent to participate in the study  for any  reason at any  
time. Withdrawal of consent occurs onl y when a participant:
Does not want to participate in the study  anymore,
and
Does not want an y further visits or assessments
and
Does not want an y further study related contacts
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the participant’s decision to withdraw his/ her consent and 
record this information.
Where consent to the use of personal and coded data is not required, participant therefore cannot 
withdraw consent. They  still retain the right to object to the further use of personal data.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
[COMPANY_001] Confidential Page 63of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Further attempts to contact [CONTACT_847542]-up.
All efforts should be made to complete the assessments prior to study  discontinuation. A final 
evaluation at the time of the participant’s study  discontinuation should be made as detailed in 
the assessment table.
[COMPANY_001]/Sponsor will continue to retain and use all research results (data) that have alread y 
been collected for the study  evaluation.
9.1.[ADDRESS_1178316] show "due diligence" by 
[CONTACT_6638], e.g. dates of 
telephone calls, registered letters, etc. A participant should not be considered as lost to follow -
up until due dil igence has been completed or until the end of the stud y.
9.1.4 Study stoppi[INVESTIGATOR_847510] y review study  data, including 
mortality  and SAEs . Enrollment in the study  will be placed on hold if any of the following 
occurs:
There is a mortality  rate which is 25% greater in the MAS825 arm than in the placebo arm 
(assessed after the first 30, 60 and 90 participants are enrolled).
The DMC or Sponsor consider that the number and/or severit y of AEs, abnormal safet y 
monitorin g tests, or abnormal laboratory  findings justify  putting the stud y on hold.
The study  may resume following the safet y review, if the Investigator and Sponsor agree it is 
safe to proceed
9.1.5 Early  study termination by  [CONTACT_157108].
Reasons for early termination (if applicable, insert additional study -specific criteria or modify  
the following criteria as per the study  set up):
Unexpected, significant, or unacceptable safety risk to participants enrolled in the st udy
Decision based on recommendations from applicable board(s) after review of safet y and 
efficacy  data
Discontinuation of study  drug development
In taking the decision to terminate, [COMPANY_001] will alway s consider participant welfare and safet y. 
Should early termination be necessary , participants must be seen as soon as possible (provide 
instruction for contact[CONTACT_90803], when the participant should stop taking drug, when 
the participan t should come in for a final visit) and treated as a prematurel y withdrawn 
participant. The investigator may  be informed of additional procedures to be followed in order 
to ensure that adequate consideration is given to the protection of the participant’s interests. 
[COMPANY_001] Confidential Page 64of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Theinvestigator or sponsor depending on local regulation will be responsible for informing 
IRBs/IECs of the early termination of the trial.
9.[ADDRESS_1178317] been documented and followed- up 
appropriatel y by [CONTACT_29517], in the event of an early  study termination decision, the date 
of that decision (e.g., each participant will be required to complete the study  in its entirety  and 
thereafter no further study  treatment will be made available to them).
Randomized and/or treated participants will have a follow -upvisit orcall conducted at Days 29, 
45 & 127. All SAEs reported during this time period must be reported as described in 
Section 10.1.3. Documentation of attempts to contact [CONTACT_847543].
Continuing care should be provided by [CONTACT_1755]/or referring physician based on 
participant availabilit y for follow -up.    
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and 
unintended sign [including abnormal laboratory  findings], symptom or disease) in a clinical 
investigation participant after providing written informed consent for participation in the study . 
Therefore, an AE may or may not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility  for managing the safety  of individual participant and 
identify ing adverse events.
[COMPANY_001] q ualified medical personnel will be readily  available to advise on trial related medical 
questions or problems.
The occurrence of adverse events must be sought by [CONTACT_105]-directive questioning of the participant 
at each visit during the study . Adverse events also may  be detected when they  are volunteered 
by [CONTACT_6643], laboratory  
test findings, or other assessments.
Adverse events must be recorded under the signs, symptoms, or diagnosis assoc iated with them, 
accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to
Section 10.1.2):
1.Severity  grade:
mild: usually  transient in nature and generally  not inter fering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities
[COMPANY_001] Confidential Page 65of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
2.Its relationship to the study  treatment. If the event is due to lack of efficacy or progression
of underl ying illness (i.e. progression of the stud y indication) the assessment of causalit y
will usually  be ‘Not suspected.’ The rationale for this guidance is that the sy mptoms of a
lack of efficacy  or progression of underly ing illness are not caused by  [CONTACT_6645], they
happen in spi[INVESTIGATOR_6532]/or both lack of efficacy  and progression of
underly ing disease can only  be evaluated meaningfull y by [CONTACT_49430], not on a
single participant
3. Its duration (start and end dates) or if the event is ongoing, an outcome of not
recovered/not resolved must be reported
4.Whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which
seriousness criteria have been met
5.Action taken regarding with study  treatment.
All adverse events must be treated appropriatel y. Treatment may include one or more of
the following:
1.Dose not changed
2.Dose Reduced/increased
3.Drug interrupted/withdrawn
6.Its outcome (i.e., recovery  status or whether it was fatal)
Conditions that were alread ypresent at the time of informed consent should be recorded in 
medical history of the participant.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing sig ns and s ymptoms.
Adverse event monitoring should be continued until the end of study . 
Once an adverse event is detected, it must be followed until its resolution or until it is judged to 
be permanent (e.g., continuing at the end of the study ), and asses sment must be made at each 
visit (or more frequently, if necessary) of an y changes in severity, the suspected relationship to 
the interventions required to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the IB.
Abnormal laboratory  values or test results constitute AEs only  if they  fulfill at least one of the 
following criteria:
1)they induce clinical signs or sy mptoms
2)they are considered clinically  significant
3)they require therapy
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically  notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non-typi[INVESTIGATOR_157049].
[COMPANY_001] Confidential Page 66of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
10.1.2 Serious A dverse Events
A Serious Adverse Event (SAE) is defined as any  adverse event [appearance of (or worsening 
of any pre-existing)] undesirable sign(s), symptom(s), or medical conditions(s) which meets 
any one of the following criteria:
Article I. fatal
Article II. life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the participant was at risk 
of death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if it were more severe (please refer to the I CH-E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospi[INVESTIGATOR_8686], unless
hospi[INVESTIGATOR_062]:
routine treatment or monitoring of the studied indication, not associated with any
deterioration in condition
elective or pre -planned treatment for a pre -existing condition that is unrelated to
the indication under s tudy and has not worsened since signing the informed
consent
social reasons and respi[INVESTIGATOR_847511]’s general condition
treatment on an emergency  outpatient basis for an event not fulfilling any  of the
defini tions of a SAE given above and not resulting in hospi[INVESTIGATOR_063]
is medically  significant, e.g., defined as an event that jeopardizes the participant or may
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately  
life threatening or result in death or hospi[INVESTIGATOR_157051]. Such events should be 
considered as “medicall y significant.” Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronc hospasm, blood dyscrasias, or convulsions that 
do not result in hospi[INVESTIGATOR_37209] (please refer to the ICH-
E2D Guidelines).
All new malignant neoplasms will be assessed as serious under “medicall y significant” if other 
seriousness criteria are not met and the malignant neoplasm is not a disease progression of the 
study  indication.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred.
[COMPANY_001] Confidential Page 67of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
10.1.[ADDRESS_1178318] be reported to [COMPANY_001] safet y 
immediately , without undue delay , under no circumstances later than 24 hours of learning of its 
occurrence. Detailed instructions regarding the submission process and req uirements are to be 
found in the investigator folder provided to each site.
Screen Failures (e.g. a participant who is screened but is not treated or randomized): SAEs 
occurring after the participant has provided informed consent until the time the partici pant is 
deemed a Screen Failure must be reported to [COMPANY_001].
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent epi[INVESTIGATOR_6537] -up to the original epi[INVESTIGATOR_847512], without undue delay , under no circumstances later than [ADDRESS_1178319] be reported 
separately  as a new event.
If the SAE is not previously documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study  treatment, a CMO & PS Department 
associate may urgently  require further information from the investigator for health authority 
reporting. [COMPANY_001] may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study  with the same study  treatment that this SAE has been 
reported.
Suspected Unexpected Serious Adverse Reactions (S[LOCATION_003]Rs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/[ADDRESS_1178320] be reported to Novar tis immediately , without undue delay , 
under no circumstances later than 24 hours of learning of its occurrence. The pregnancy  should 
be followed up to determine outcome, including spontaneous or voluntary  termination, details 
of the birth, and the presence or absence of any birth defects, congenital abnormalities, or 
maternal and/or newborn complications.
Pregnancy  should be recorded and reported by [CONTACT_37288]  (CMO&PS). Pregnancy  follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study  treatment any 
pregnancy  outcome. Any SAE experienced during pregnancy  must be reported.
The newborn will be followed up for a minimum of 1 month after d elivery.
[COMPANY_001] Confidential Page 68of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, participant or 
consumer (European Medicines Agency  (EMA) definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal 
product, which is accompanied by  [CONTACT_50104].
Study  treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF irrespective of whether or not associated with an AE/SAE and reported to 
Safety  only if associated with an SAE. Misuse or abuse will be collected and reported in the 
safet y database irrespective of it being associated with an AE/SAE within 24 hours of 
Investigator’s awareness.
Table 10-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in Dosing 
CRF (Yes/No)Document in A E 
eCRFComplete SA E form
Unint entional study 
treatment errorYes Only if associated with 
an AEOnly if associated with 
an SAE
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE
For more information on AE and SAE definition and reporting requirements, please see the 
respective Section 10.1.1 , Section 10.1.2 and Section 10.1.3.
10.2 Additional safety  monitoring
10.2.1 Liver safety monitoring
To ensure participant safety  and enhance reliabi lityin determining the hepatotoxic potential of 
an investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be followed.
Please refer to Table 16-1 in Appendix 3 for complete definitions of liver laboratory triggers.
Once a participant is exposed to study  treatment, every  liver event defined in Table 16-2 should 
be followed up by [CONTACT_847544], as summarized below. 
Additional details on actions required in case of liver events are outlined in Table 16 -2
. Repeat 
liver chemistry  tests (i.e., AL T, AST, TBL, PT/INR, AL P and G- GT) to confirm elevation.
These liver chemistry  repeats should be performed using the local laboratory  used by  [CONTACT_331581]. Repeated laboratory  test results must be reported as appropriate.
If the initial elevation is confirmed, close observation of the participan t will be initiated,
including consideration of treatment interruption if deemed appropriate.
Hospi[INVESTIGATOR_6539]
Causality  assessment of the liver event
[COMPANY_001] Confidential Page 69of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Thorough follow -up of the liver event should include
Based on investigator’s discretion: serology  tests, imaging and pathology assessments,
hepatologist’s consultancy ; obtaining more detailed history  of symptoms and prior or
concurrent diseases, history  of concomitant drug use, exclusion of underly ing liver
disease
All follow -up information and procedures performed must be recorded as appropriate in the 
CRF.
10.2.2 Data Monitoring Committee
This study  will include a Data Monitoring Committee (DMC) which will function 
independentl y of all other individuals associated with theconduct of this clinical trial, including 
the site investigators participating in the study . The committee will include [COMPANY_001] employ ees 
and at least one external medical expert. The DMC will assess at defined intervals the progress 
of a clinical trial, safet y data, and critical efficacy  variables and recommend to the sponsor 
whether to continue, modify , or terminate a trial.
Specific details regarding composition, responsibilities, data monitoring, and meeting 
frequency , and documentation of DMC reports , minutes, and recommendations will be 
described in a separate charter that is established between the sponsor and the DMC
[ADDRESS_1178321] that allows its accurate reporting, 
interpretation, and ve rification.
Designated investigator staff will enter the data required by [CONTACT_37290] (eCRF). The eCRFs have been built using fully validated secure web-
enabled software that co nforms to 21 CFR Part 11 requirements, Investigator site staff will not 
be given access to the electronic data capture (EDC) system until they have been trained. 
Automatic validation programs check for data discrepancies in the eCRFs, allow modification 
and/or verification of the entered data b y the investigator staff.
The investigator/designee is responsible for assuring that the data (recorded on CRFs) (entered 
into eCRF) is complete, accurate, and that entry and updates are performed in a timely  manner. 
The Investigator must certify  that the data entered are complete and accurate.
After final database lock, the investigator will receive copi[INVESTIGATOR_157052].
All data should be recorded, handled, and stored in a way that allows its accurate reporting, 
interpretation, and verification.
11.2 Database management and quality  control
[COMPANY_001] personnel (or designated Clinical Research Organization (CRO)) will review the data 
entered by [CONTACT_5375] . Electronic data queries stating 
[COMPANY_001] Confidential Page 70of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
the nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the investigational site via the EDC s ystem. Designated investigator 
site staff a re required to respond promptly to queries and to make an y necessary  changes to the 
data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemi cal (ATC) 
classification system. Medical history /current medical conditions and adverse events will be 
coded using the Medical Dictionary  for Regulatory  Activities (MedDRA) terminology .
Screenings, randomizations, exit statuses, as well as randomization codes and data about all 
treatment arms assigned to the participant will be tracked using an Interactive Response 
Technology  (IRT). 
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will belocked and made available for data analy sis/moved to restricted 
area to be accessed by [CONTACT_49433]. Any changes to the database 
after that time can only be made after written agreement by [CONTACT_188660]
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a [COMPANY_001] 
representative will review the protocol and data capture requirements (i.e. eSource Direct Data 
Entry  (DDE) or eCRFs) with the investigators and their staff. During the study , [COMPANY_001] 
employ s several methods of ensuring protocol and GCP compliance and thequality /integrity  of 
the site’s data. The field monitor will check the completeness of participant records, the 
accuracy  of data capture / data entry, the adherence to the protocol and to GCP, the progress of 
enrollment, and to ensure that study  treatment is being stored, dispensed, and accounted for 
according to specifications. Key study personnel must be available to assist the field monitor 
during these visits. Continuous remote monitoring of each site’s data may be performed by a 
centralized [COMPANY_001] clinical research associate organization. Additionally , a central analytics 
organization may analyze data & identify  risks & trends for site operational parameters and 
provide reports to [COMPANY_001] clinical teams to assist with trial oversight.
The investigator must maintain source documents for each participant in the study , consisting 
of case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information on CRFs must be traceable to these source documents in the 
participant's file. The investigator must also keep theoriginal ICF signed by [CONTACT_2299] 
(asigned copy is given to the participant).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . Source data verificati on may be done on-
site, if possible, or remotely, if the field monitor does not have access or have limited access to 
the site due to the current COVID -[ADDRESS_1178322] adhere to the recommendations established by [CONTACT_371939].
[COMPANY_001] Confidential Page 71of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
[COMPANY_001] monitoring standards require full verification for the presence of informed consent, 
adherence to the inclusion/exclusion criteria, documentation of SAEs, and of data that will be 
used for all primary  variables. Additional checks of the consistency  of the source data with the 
CRFs are performed according to the stud y-specific monitoring plan. No information in source 
documents about the identity  of the participants will be disclosed.
12 Data analy sis and statistical methods
Any data analy sis carried out independently  by [CONTACT_85689]. The anal ysis will be conducted on all participant data at the 
time the trial ends.
12.1 Analysis sets
For all analysis sets, participants will be analy zed according to the study  treatment(s) 
randomize d. 
The Safet y analysis set will include all randomized participants that have received any study 
drug.
The PD analysis set will include all randomized participants with no protocol deviations with 
relevant imp act on PD data.
12.[ADDRESS_1178323] deviation, median, 25th and 
75th percentiles, minimum, and maximum w ill be presented.
The dates and times of MAS825 dosing will be listed.
Concomitant medications and significant non-drug therapi[INVESTIGATOR_49344] (ATC) classification sy stem, by  [CONTACT_1570].
Commercially Confidential Information 
[COMPANY_001] Confidential Page 72of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
12.4 Analysis of the primary  endpoint(s)/estimand(s)
The primary  aim of the study  is to evaluate the effect of MAS825 compared with placebo on 
the APACHE II score. A decrease in the score is considered a favourable outcome.
12.4.1 Definition of primary  endpoint(s)/estimand(s)
The primary  estimand, including the primary  endpoint is defined in Section 2.1 of this protocol. 
It is based on the APACHE -II score.
12.4.2 Statistical model, hypoth esis, and method of analy sis
The primary  endpoint will be evaluated by [CONTACT_847545]- II score as a covariate. 
The analysis will be performed on the safet y analysis set. The mean differences of MAS825 vs 
placebo will be reported with 90% confidence intervals (CIs). The 1-sided p-value for the 
overall treatment factor will be reported.
The primary  objective will be achieved if the null hypothesis that MAS825 is not different to 
placebo is rejected using a one side alpha of 10%. 
12.4.3 Handling of remaining intercurrent events of primary  estimand
As described in Section 2.1 , discontinuation of study  treatment for any reason will be ignored. 
12.4.4 Handling of missing values not related to intercurrent event
Handling of missing APACHE II  scores or components of APACHE II scores at Day  15 or on 
day of discharge will be specified in the SAP.
12.4.5 Sensitivity analy ses for primary  endpoint/estimand
If there are imbalances in demographic or baseline characterist ics between the two treatment 
groups, then an ANCOVA model similar to the primary  analysis model with the additional 
inclusion of these demographic or baseline characteristics as covariates may  be fitted.
12.4.6 Supplementary  analysis
Not applicable
12.4.7 Supportive analy ses
Not applicable .
12.5 Analysis of secondary  endpoints/estimands
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s)
Descriptive statistics (mean, standard deviation, median, minimum and maximum) will be 
provided for variables that are of the numeric or continuous type, while frequency  distributions 
(with number and percent) will be provided for categorical variables.
[COMPANY_001] Confidential Page 73of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Analy ses of the hospi[INVESTIGATOR_847513] .
12.5.2 Safety  endpoints
For all safet y analyses, the safet y set will be used. All listings and tables will be presented by 
[CONTACT_1570]. 
Safety  summaries (tables, figures) include only data from the on-treatment period with the 
exception of baseline data wh ich will also be summarized where appropriate (e.g. change from 
baseline summaries). In addition, a separate summary  for death including on treatment and post 
treatment deaths will be provided. In particular, summary  tables for adverse events (AEs) will 
summarize only on-treatment events, with a start date during the on-treatment period 
(treatment -emergent AEs).
.
[IP_ADDRESS] Adverse events
All information obtained on adverse events will be display ed by [CONTACT_131373].
The number (and percentage) of participants with treatment emergent adverse events (events 
started after the first dose of study  medication or events present prior to start of randomized 
treatment but increased in severit y based on preferred term) will be summarized in the following 
ways:
by [CONTACT_3148], primary  system organ class and preferred term.
by [CONTACT_3148], primary  system organ class, preferred term and maximum severity .
Separate summaries will be provided for study  medication related adverse events, death, serious 
adverse events and other significant adverse events leading to discontinuation.
[IP_ADDRESS] Vital signs
All vital signs data will be listed by [CONTACT_1570], participant, and visit/time and if ranges 
are available, abnormalities (and relevant orthostatic changes) will be flagged. 
Summary statistics will be provided by  [CONTACT_10659]/time.
[IP_ADDRESS] ECG s
PR, QRS, QT, QTcF, and RR intervals will be obtained from ECGs for each participant during 
the study . ECG data will be read and interpreted locally .
Categorical analysis of QT/QTcF inter val data based on the number of participants meeting or 
exceeding predefined limits in terms of absolute QT/QTcF intervals or changes from baseline 
will be presented. In addition, a listing of these participants will be produced by [CONTACT_1570].
All ECG data will be listed by [CONTACT_1570], participant and visit/time, abnormalities will be 
flagged. Summary  statistics will be provided by  [CONTACT_10659]/time.
[COMPANY_001] Confidential Page 74of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
[IP_ADDRESS] Clinical laboratory  evaluations
All laboratory  data will be listed by [CONTACT_1570], participant, and visit/time and if normal 
ranges are available abnormalities will be flagged. Summary  statistics will be provided by 
[CONTACT_10659]/time. 
Serum CRP levels will be analyzed on a log-scale fitting a repeated measures mixed model 
including treatment group, study  day, the three stratification factors and log transformed 
baseline CRP as a covariate. I nteractions between study  day and each of the terms in the model 
will also be included. The back -transformed ratios of MAS825 vs placebo will be reported with 
90% CIs. The 1-sided p-value for the overall treatment factor will be reported. Ferritin levels 
will also be anal yzed in the same manner.
[IP_ADDRESS] Other safety  evaluations 
The proportion of participants who have a positive SARS -CoV -[ADDRESS_1178324] will be summ arized by 
[CONTACT_6982].
12.6 Analysis of exploratory  endpoints
Commercially Confidential Information 
Commercially Confidential Information 
[COMPANY_001] Confidential Page 75of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
12.9 Sample size calcul ation
12.9.1 Primary  endpoint(s)
The sample size is limited to maximum of 60 participants to be treated with a single i.v.dose of 
MAS825 due to limitations in the available drug supply  at this point in time.To establish clinical 
efficacy  based on APACHE II score a sample size of 60 participants per treatment group 
provides 80% power when testing on an 10% 1-sided alpha level under the assumption that 
MAS825 reduces the APACHE II score by 3.6 points more than placebo (assumed standard 
deviation of 9.2 based on Yang et al 2020).
12.9.2 Secondary  endpoint(s)
For the analysis of CRP a sample size of 60 participants per treatment group provides 80% 
power when testing on a 1% 1-sided alpha level under the assumption that MAS825 reduces 
CRP by 44% more than placebo (assumed CV of 130% based on the range of variability 
observed in Chen et al 2020 and prev ious studies with canakinumab) .
13 Ethical considerations and administrative procedures
13.1 Regulatory  and ethical compliance
This clinical study  was designed and shall be implemented, executed and reported in accordance 
with the ICH Harmonized Tripartite Guideli nes for Good Clinical Practice (GCP), with 
applicable local regulations (including European Direct ive 2001/20/EC, US CFR 21), and with 
the ethical principles laid down in the Declaration of Helsinki.
Commercially Confidential Information 
[COMPANY_001] Confidential Page 76of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
13.2 Responsibilities of the investigator and IRB/IEC
Before initiating a trial, the investigator/institution must obtain approval/favorable opi[INVESTIGATOR_18548]/Independent Ethics Committee (I RB/IEC) for the trial protocol, 
written ICF, consent form updates, participant recruitment procedures (e.g., advertisements) 
and any other written information to be provided to participants. Prior tostudy  start, the 
investigator is required to sign a protocol signature [CONTACT_5389]/her agreement to 
conduct the study  in accordance with these documents and all of the instructions and procedures 
found in this protocol and to give access to all relevant data and records to[COMPANY_001] monitors, 
auditors, [COMPANY_001] Quality  Assurance representatives, designated agents of [COMPANY_001], IRBs/IECs, 
and regulatory  authorities as required. If an inspection of the clinical site is requested by a 
regulatory  authority , the investigator must inform [COMPANY_001] immediately  that this request has 
been made.
13.3 Publication of study  protocol and results
The protocol will be registered in a publicly  accessible database such as clinicaltrials.gov. 
Inaddition, after study  completi on (defined as last patient last visit) and finalization of the study  
report the results of this trial will be submitted for publication and posted in a publi cly accessible 
database of clinical trial results, such as the [COMPANY_001] clinical trial results website and all required
Health Authority  websites (e.g., clinicaltrials.gov, etc.) .
For details on the [COMPANY_001] publication policy  including authorship criteri a, please refer to the 
[COMPANY_001] publication policy training materials that were provided to you at the trial investigator 
meetings.
13.[ADDRESS_1178325] Quality  Management System (QMS) that includes all activiti es 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guidelines.
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk -based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to writ ten [COMPANY_001] processes.
[COMPANY_001] Confidential Page 77of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
[ADDRESS_1178326] be 
considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_6669]/IEC and Health Authorities, where required, it cannot be 
implemented.
14.[ADDRESS_1178327] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to 
implementation.
Only  amendments that are required for participant safety  may be implemented immediately  
provided the health authorities are subsequently  notified by [CONTACT_37306]/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any  immediate action required for the safet y of any participant included in this 
study , even if this action represents a deviation from the protocol. In such cases, [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study  site should be informed according to 
local regulations.
[COMPANY_001] Confidential Page 78of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
[ADDRESS_1178328]
A Study  to Evaluate the Safety  and Efficacy  ofTocilizumab in Patients With Severe COVID -
19 Pneumonia (COVACTA) https://clinicaltrials.gov/ct2/show/[STUDY_ID_REMOVED] (accessed 22nd 
April 2020)
Abdel Fattah E, Bhattachary a A, Herron A,et al (2015) Critical role for IL-18 in spontaneous 
lung inflammation caused by  [CONTACT_847546] . J Immunol 194: 5407-5416.
Afonina IS, Muller C, Martin SJ,et al (2015) Proteoly tic Processing of Interleukin-1 Famil y 
Cytokines: Variations on a Common Theme. Immunity  42: 991
-1004.
Ascierto PA, Fox B, Urba W, et al (2020) Insights from immuno -oncology: the Society  for 
Immunotherap y of Cancer Statement on access to IL-6-targeting therapi[INVESTIGATOR_135297] -
19. J 
Immunother Cancer 8.
Belkay a SE, Michailidis CB, Korol M,et al (2019) Inherited IL-18BP deficiency  in human 
fulminant viral hepatitis. J Exp Med 216: 1777- 1790. 
Cameron LA, Taha RA, Tsicopoulos A, et al (1999) Airway  epi[INVESTIGATOR_847514] -
18. Eur Respir J 14: 553-559. 
Canna SW, Girard C, Malle L
, et al (2017 )Life-threatening NLRC4-associated
hyperinflammation successfully  treated with IL-18 inhibition. J Allergy Clin Immunol 139: 
1698-1701.
Cao Y, Li Q, Chen J, et al (2020) Hospi[INVESTIGATOR_847515] -
19 Epi[INVESTIGATOR_901]. Acad Emerg Med 27: 309
-311.
Chakrabort y A, Tannenbaum S, Rordorf C, et al (2012) Pharmacokinetic and pharmacod ynamic 
properties of canakinumab, a human anti-interleukin -1β monoclonal antibody .Clin 
Pharmacokin 51: e1- e18.
Chen N, Zhou M, Dong X, et al (2020) Epi[INVESTIGATOR_847516] 99 cases 
of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study . Lancet; 
395([ZIP_CODE]):507-13.
Coates BM, Staricha KL, Ravindran N, et 
al (2017) Inhibition of the NOD- Like Receptor 
Protein 3 Inflammasome Is Protective in Juvenile Influenza A Virus Infection. Front Immunol 
8: 782. 
Eckle T, Fullbier L, Wehrmann M, et al (2007) Identification of ectonucleotidases CD39 and 
CD73 in innate protection during acute lung injury . J Immunol 178: 8127- 8137.
FDA (2003) Guidance for Industry  – Pharmacokinetics in patients with impaired hepatic 
function: study  design, data anal ysis, and impact on dosing and labeling. Rockville, MD: Food 
and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for 
Biologics Evaluation and Research (CBER), May  2003.
[COMPANY_001] Confidential Page 79of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Franchi L, Eigenbrod T, Munoz -Planillo R, et al (2014) Cytosolic double -stranded RNA 
activates the NLRP3 inflammaso me via MAVS -induced membrane permeabilization and K+ 
efflux. J I mmunol 193: 4214-4222. 
Hasan D, Blankman P, and Nieman GF (2017) Purinergic signalling links mechanical breath 
profile and alveolar mechanics with the pro-inflammatory  innate immune response causing 
ventilation -induced lung injury . Purinergic Signal 13: 363 -386.
Horvath GL, Schrum JE, De Nardo CM, et al (2011) Intracellular sensing of microbes and 
danger signals b y the inflammasomes. I mmunol Rev 243: 119-135.
Huang KJ, SuIJ, Theron M, et al ( 2005) An interferon -gamma -related cytokine storm in SARS 
patients. J Med Virol 75: 185-194.
Huang C, Wang Y, Li X, et al(2020) Clinical features of patients infected with 2019 novel 
coronavirus in Wuhan, China. The Lancet, 395: 497 -506.
Ichinohe T, LeeHK, Ogura Y, et al (2009) Inflammasome recognition of influenza virus is 
essential for adaptive immune responses. J Exp Med 206: 79-87.
Jia X, Liu B, Bao L, et al (2018) Dela yed oseltamivir plus sirolimus treatment attenuates H1N1 
virus -induced severe lung injury  correlated with repressed NLRP3 inflammasome activation 
and inflammatory  cell infiltration. PLoS Pathog 14: e1007428.
Kang MJ, Choi JM, Kim BH, et al (2012) IL-[ADDRESS_1178329]  and vascular 
remodeling via IFN -gamma, IL -17A, and IL -
13. Am J Respir Crit Care Med 185: [ADDRESS_1178330] ama T, Okamoto M, Imaoka H, et al (2012) Interleukin -18 in pulmonary  inflammatory 
diseases. J I nterferon C ytokine Res 32: 443-449.
Knaus WA, Draper EA, Wagner DP, et al (1985) APACHE II: a severity  of diseas e 
classification s ystem. Crit Care Med 13: 818 -829.
Kolb M, Margetts PJ, Anthony DC, et al (2001) Transient expression of IL -1beta induces acute 
lung injury  and chronic repair leading to pulmonary  fibrosis. J Clin I nvest 107: 1529
-1536.
Kuipers MT, Aslami H, Janczy JR, et al(2012) Ventilator induced lung injury  is mediated by 
[CONTACT_847547]3 inflammasome. Anesthesiology  116: 1104 -1115.
Liu H, Gu C, Liu M, et al (2019) Ventilator -induced lung injury  is alleviated by [CONTACT_847548]3 inflammasome activation. Mol Immunol 111: 1 -
10.
Lv Z, Wang Y, LiuYJ, et al (2018) NLRP3 Inflammasome Activation Cont ributes to 
Mechanical Stretch- Induced Endothelial -Mesenchy mal Transition and Pulmonary  Fibrosis. 
Crit Care Med 46: e49 -e58.
Matsuy ama H, Amay aF, Hashimoto S, et al (2008) Acute lung inflammation and ventilator -
induced lung injury  caused by [CONTACT_847549] P2Y receptors: an experimental study . Respir Res 
9: 79.
     Commercially Confidential Information 
[COMPANY_001] Confidential Page 80of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
McAuley  JL, TateMD, MacKenzie -Kludas CJ, et al (2013) Activation of the NLRP3 
inflammasome by [CONTACT_847550]1-F2 contributes to severe pathophy siology  and 
disease. PLoS Pathog 9: e1003392.
Mehta P, McAuley DF, Brown M, et al (2020) COVID- 19: consider cytokine storm syndromes 
and immunosuppression. L ancet 395:1033–4.
Moghaddas F, Zeng P, Zhang Y ,et al (2018) Autoinflammatory  mutation in NL RC4 reveals a 
leucine -rich repeat (LRR) -LRR oligomerization interface. J Allergy  Clin Immunol 142: 1956 -
1967 e1956.
Olman MA, White KE, Ware LB, et al (2004) Pulmonary edema fluid from patients with early 
lung injury  stimulates fibroblast proliferation through IL-1 beta-induced IL-6 expression. J 
Immunol 172: 2668- 2677.
Pugin J, Ricou B, Steinberg KP, et al (1996) Proinflammatory  activity  in bronchoalveolar 
lavage fluids from patients with ARDS, a prominent role for interleukin -1. Am J Respir Crit 
Care Med 153: 1850- 1856. 
Ren R, Wu S, CaiJ, et al (2017) The H7N9 influenza A virus infection results in lethal 
inflammation in the mammalian host via the NLRP 3-caspase-1 inflammasome. Sci Rep 7: 7625.
Study  Report No. RD-2016 -
[ZIP_CODE] (2018) Effects of combined IL-1β and IL-18 stimulation and 
blockade in PBMC.
Tate MD, Ong JDH, Dowling JK, et al (2016) Reassessing the role of the NLRP3 
inflammasome during pathogenic influenza A virus infection via temporal inhibition. Sci Rep 
6: [ZIP_CODE]. 
Teasdal, G andJennett, B. (1974). Assessment of coma and impaired consciousness: A 
Practical Scale. The Lancet. Volume 304, Issue 7872, Pages 81 -84.
Vanden Berghe T, Demon D, Bogaert P, et al (2014) Simultaneous targeting of IL -[ADDRESS_1178331] inflammatory  and septic shock. Am J Respir Crit Care Med 
189: 282-291.
Vincent JL, Rello J, Marshall J, et al (2009) International Study  of the Prevalence and Outcomes 
of Infection in I ntensive Care Units. JAMA Vol. 302(21):2323 -
2329.
Wang D, Hu B, Hu C, et al (2020) Clinical characteristics of 138 hospi[INVESTIGATOR_9645] 
2019 Novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. doi: 
10.1001/jama.2020.1585. [Epub ahead of print].
WHO (2020) COVID -19 Therapeutic Trial Synopsis. Geneva, Switzerland: WHO R&D 
Blueprint, Feb 18 2020.
Commercially Confidential Information 
[COMPANY_001] Confidential Page 81of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Wu J, Yan Z, Schwartz DE, et al (2013) Activation of NLRP3 inflammasome in alveolar 
macrophages contributes to mechanical stretch -induced lung inflammation and injury . 
JImmunol 190: 3590- 3599.
Yan X, Chen Y and Krzyz anski W (2012) Methods of solving rapid binding target -mediated 
drug disposition model for two drugs competing for the same receptor. Journal of 
pharmacokinetics and pharmacod ynamics 39; 543-560.
Yang X, Yu Y, Xu J, et al (2020) Clinical course and outcomes of critically  ill patients with 
SARS -CoV -2 pneumonia in Wuhan, China: a single -centered, retrospective, observational 
study . Lancet Respir Med.
Zhang Y, LiJ, Zhan Y, et al (2004) Analy sis of serum cytokines in patients with severe acute 
respi[INVESTIGATOR_7497]. Infect Immun 72: 4410 -4415. 
Zhang X, Song K, Tong F, et al (2020) First case of COVID -19 in a patient with multiple 
myeloma successfull y treated with tocilizumab. Blood Adv 4: 1307 -1310.
Zhang LM, Zhang Y, Fei C, et al (2019) Neutralization of IL-18 by [CONTACT_8668]-18 binding protein 
ameliora tes bleom ycin-induced pulmonary  fibrosis via inhibition of epi[INVESTIGATOR_018] -mesench ymal 
transition. Biochem Biophy s Res Commun 508: 660-666.
Zhou F, YuT, DuR,et al(2020) Clinical course and risk factors for mortality  of adult inpatients 
with COVI D-19 in Wuha n, China: a retrospective cohort study . Lancet.
[COMPANY_001] Confidential Page 82of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
16 Appendices
16.1 Appendix 1: Anaphy laxis
Anaph ylaxis is highly  likely  when any  one of the following 3 criteria are fulfilled:
1.Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal 
tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips -tongue -uvula)
AND AT LEAST ONE OF THE FOLLOWING
a.Respi[INVESTIGATOR_11310] (e.g., dyspnea, wheeze -bronchospasm, stridor, reduced PEF, 
hypoxemia)
b.Reduced BP or associated symptoms of end-organ dysfunction (e.g., hypotonia 
[collapse], sy ncope, incontinence)
2.Two or more of the following that occur rapi[INVESTIGATOR_11312] a likely  allergen for that 
patient (minutes to several hours):
a.Involvement of the skin-mucosal tissue (e.g., generalized hives, itch-flush, swollen lips-
tongue -uvula)
b.Respi[INVESTIGATOR_11310] (e.g., dyspnea, wheeze -bronchospasm, stridor, reduced PEF, 
hypoxemia)
c.Reduced BP or associated symptoms (e.g., hypotonia [collapse], syncope, incontinence)
d.Persistent gastrointestinal sy mptoms (e.g., crampy abdominal pain, vomiting)
3.Reduced BP after exposure to known allergen for that patient (minutes to several hours):
a.Adults: sy stolic BP of less than 90 mm Hg or greater than 30% decrease from baseline .
[COMPANY_001] Confidential Page 83of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
16.2 Appendix 2: [ADDRESS_1178332] assessment of a given study 
day. Each da y, the worse score for the previous day will be recorded. i.e. on Day 3, Da y 2 score 
is obtained and recorded as Day  2.
The scale is as follows:
Patient State  Descriptor   Score
Uninfected No clinical or virological evidence of infection 0
Ambulatory No limitation of activities 1
Limitation of activities 2
Hospi[INVESTIGATOR_701782], no ox ygen therapy 3
Oxygen by [CONTACT_88543] 4
Hospi[INVESTIGATOR_701783]-invasive ventilation or high- flow oxygen 5
Intubation and mechanical ventilation 6
Ventilation + additional organ support -pressors, RRT, 
ECMO7
Dead Death 8
Source: ( WHO 2020)
[COMPANY_001] Confidential Page 84of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
16.3 Appendix 3: Liver event and laboratory trigger definitions & 
follow -up requirements
Table 16-1 Liver event and laboratory  trigger definitions
Definition/ threshold
Liver laboratory triggers
If ALT, AST and total bilirubin normal at 
baseline: ALT or AST > 5 × ULN
ALP > 2 × ULN (in the absence of known bone 
pathology)
Total bilirubin > 3 × ULN (in the absence of known 
Gilbert syndrome)
ALT or AST > 3 × ULN and INR > 1.5
Potential Hy’s Law cases (defined as ALT or AST > 
3 × ULN and Total bilirubin > 2 × ULN [mainly 
conjugated fraction] without notable increase in ALP 
to > 2 × ULN)
Any clinical event of jaundice (or equivalent te rm)
ALT or AST > 3 × ULN accompanied by (general) 
malaise, fatigue, abdominal pain, nausea, or 
vomiting, or rash with eosinophilia
Any adverse event potentially indicative of a liver 
toxicity*
If ALT or AST abnormal at baseline: ALT or AST > 3x baseline or > 300 U/L (whichever 
occurs first)
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; non -infectious hepatitis; benign, malignant and unspecified liver neoplasms ULN: 
upper limit of normal
[COMPANY_001] Confidential Page 85of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Table 16-2 Follo w up requirements for liver laboratory  triggers
Criteria Actions required Follow -up monitoring
Total Biliruin (isolated)
>1.5 –3.[ADDRESS_1178333] Repeat LFTs within 48 -72 
hoursMonitor LFTs weekly until 
resolutioncto ≤ Grade 1 or to 
baseline
> 3 -10 × ULN (in the absence 
of known Gilbert s yndrom e)Repeat LFT within 48 -72 
hours
Establish causality
Record the AE and 
contributing factors (e.g. 
conmeds, med hx, lab) in 
the appropriate CRFMonitor LFTs weekly until 
resolutioncto ≤ Grade 1 or to 
baseline (ALT, AST, total 
bilirubin, Alb, PT/INR, ALP and 
GGT) 
Test for hemoly sis (e.g. 
reticulocytes, haptoglobin, 
unconjugated [indirect] 
bilirubin)
> [ADDRESS_1178334] Establ ish causality
Record the AE and 
contributing factors(e.g. 
conmeds, med hx, lab)in 
the appropriate CRFALT, AST, total bilirubin, Alb, 
PT/INR, ALP and GGT until 
resolutionc(frequency at 
investigator discretion)
Any AE potentially indicative of 
a liver tox icity*Hospi[INVESTIGATOR_157055]
Establish causality
Record the AE and 
contributing factors(e.g., 
conmeds, med hx, lab)in 
the appropriate CRFInvestigator discretion
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash with eosinophilia 
cResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent mon itoring visits at least 2 weeks apart, (3) remain at elevated level 
after a maximum of 6 months, (4) liver transplantation, and (5) death.
Based on investigator’s discretion investigation(s) for contributing factors for the liver event 
can include: Serolo gy tests, imaging and pathology  assessments, hepatologist’s consultancy ; 
obtaining more detailed history  of symptoms and prior or concurrent diseases, history  of 
concomitant drug use, exclusion of underl ying liver disease.
[COMPANY_001] Confidential Page 86of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
16.4 Appendix 4: ICU scores 
Table 16-3 APAC HE II
Variable Unit
Age years
Glasgow Coma Score
Vitals Body tem peratureoC
Mean arterial pressure (MAP) mmHg
Heart rate bpm
Respi[INVESTIGATOR_847517]/m
Oxygenation FiO 2 %
PaO 2 mmHg
Arterial pH
PaCO 2
Altitude of sitemmHg
Meters above sea level
Chemistry Sodium mEq/L
Potassium mEq/L
Creatinine mg/dL
Acute Renal Failure Yes/No
Hematology Hematocrit %
White blood cell (W BC) count x109/L
Severe organ system 
insufficiency or is 
immunocompromisedYes/No
Source: ( Knaus et al 1985 )
[COMPANY_001] Confidential Page 87of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Table 16-4 Estimating PaO 2from a given S pO 2
SpO 2 (%) PaO 2 (mmHg) PaO 2 (mmHg)
80 44
81 45
82 46
83 47
84 49
85 50
86 52
87 53
88 55
89 57
90 60
91 62
92 65
93 69
94 73
95 79
96 86
97 96
98 112
99 145
Source : (Vincent et al 2009 )
[COMPANY_001] Confidential Page 88of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Table 16-5 Estimating FiO 2
Method O2flow (l/min) Estimated FiO 2(%)*
Nasal cannula 1 24
2 28
3 32
4 36
5 40
6 44
Nasopharyngeal catheter 4 40
5 50
6 60
Face mask 5 40
6-7 50
7-8 60
Face mask with reservoir 6 60
7 70
8 80
9 90
10 95
Source : (Vincent et al 2009 )
* If patient is breathing air then estimated Fi02 is 21%
[COMPANY_001] Confidential Page 89of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Commercially Confidential Information 
[COMPANY_001] Confidential Page 90of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
Table 16-[ADDRESS_1178335] 
and dateOrientated 5
Not orientated but 
communication coherentlyConfused 4
Intelligible single words Words 3
Only moans/groans Sounds [ADDRESS_1178336] Obeys commands 6
Brings hand above clavicle to 
stimulus on head neckLocalising 5
Bends arm at elbow rapi[INVESTIGATOR_2478] y, but 
features not predominantly 
abnormalNormal flexion 4
Bends arm at elbow, features 
clearly predominantly abnormalAbnormal flexion 3
Extends arm at elbow Extension 2
No mo vement in arms/legs, no  
interfering factorNone 1
Paralysed or other limiting 
factorNon testable NT
Source: ( Teasdal andJennett 1974 )
[COMPANY_001] Confidential Page 91of 91
Amended Protocol Version 01 (Clean ) Protocol No. CMAS825F12201
16.5 Appendix 5: Severity  of hepatic impairment (Child-Pugh)
Points scored for observed 
findings
1 point 2 points 3 points
Encephalopathy grade* Absent 1 or2 3 or 4
Ascites Absent Slight Moderate
Serum bilirubin(µmol/L) <34.2 34.2 –51.3 >51.3
Serum albumin (g/L) >35 28 –35 <28
Prothrombin time (INR) <1.16 1.16 –1.56 >1.56
Classification
Child- Pugh grade Child- Pugh A Child- Pugh B Child- Pugh C
Points required 5 – 6 7 – 9 10 –15
*Grade 0: normal consciousness, personality, neurological examination, electroencephalogram
Grade 1: restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting, 5 cps waves
Grade 2: lethargic, tim e-disoriented, inappropriate, asterixis, ataxia, slow triphasic waves
Grade 3: somnolent, stuporous, place -disoriented, hyperactive reflexes, rigidity, slower waves
Grade 4: unrousable coma, no personality/behavior, decerebrate, slow 2 -3 cps delta activ ity
Source: ( FDA 2003 )